
THE LAW AND
REGULATION OF
MEDICINES AND
MEDICAL DEVICES
SECOND EDITION

EDITED BY
PETER FELDSCHREIBER



OXFORD

The Law and Regulation of Medicines and Medical Devices

The Law and Regulation of Medicines and Medical Devices

Second Edition

Edited by

PETER FELDSCHREIBER

Barrister 4 New Square, Lincolns' Inn

OXFORD
UNIVERSITY PRESS

OXFORD

UNIVERSITY PRESS

Great Clarendon Street, Oxford, OX2 6DP,
United Kingdom

Oxford University Press is a department of the University of Oxford.
It furthers the University's objective of excellence in research, scholarship,
and education by publishing worldwide. Oxford is a registered trade mark of
Oxford University Press in the UK and in certain other countries

© Oxford University Press 2021

The moral rights of the authors have been asserted

First Edition published in 2008

Second Edition published in 2021

Impression: 1

All rights reserved. No part of this publication may be reproduced, stored in
a retrieval system, or transmitted, in any form or by any means, without the
prior permission in writing of Oxford University Press, or as expressly permitted
by law, by licence or under terms agreed with the appropriate reprographics
rights organization. Enquiries concerning reproduction outside the scope of the
above should be sent to the Rights Department, Oxford University Press, at the
address above

You must not circulate this work in any other form
and you must impose this same condition on any acquirer

Public sector information reproduced under Open Government Licence v3.0
(<http://www.nationalarchives.gov.uk/doc/open-government-licence/open-government-licence.htm>)

Published in the United States of America by Oxford University Press
198 Madison Avenue, New York, NY 10016, United States of America

British Library Cataloguing in Publication Data

Data available

Library of Congress Control Number: 2021934719

ISBN 978-0-19-284754-6

DOI: 10.1093/oso/9780192847546.001.0001

Printed and bound in the UK by
TJ Books Limited

Links to third party websites are provided by Oxford in good faith and
for information only. Oxford disclaims any responsibility for the materials
contained in any third party website referenced in this work.

Foreword

I am delighted to be asked to supplement my Foreword to the First Edition with a new Foreword to this magnificent, and substantially expanded and updated, Second Edition, save that, twelve years on, I can no longer subscribe myself as ‘Queens Bench Division,’ though I am keeping in touch with litigation by sitting from time to time in the Commercial Court and as an arbitrator! When I wrote the first Foreword, at the invitation of the learned Editor as I was one of the few judges who had dabbled in the new field (as referred to in Chapter 9 now twenty years ago), I described the new work as an exciting addition to the law library. I could have described it as radical, in drawing together the threads of medico-pharmaceutical law for the first time in one place. But, twelve years on, I must now describe this work as more than radical, rather as revolutionary, for it constitutes the consolidation of a new jurisprudence, just at the time it is desperately needed. What timing! As I write this Foreword, we are in continuing lockdown, and the ‘new normal’ is inevitably going to involve a dramatic increase, first in the need for analysis of legal and regulatory problems and solutions, and then, I am sure, in litigation, as researchers, pharmacologists, doctors, regulators, lawyers, and in due course judges address the ongoing impact of Covid, both in the pharmaceutical field and in the development and resolution of post-Covid disputes. Looking at the breadth and depth of its coverage, this book is not just a useful but a vital tool. Its in-depth analyses and its up-to-date assessments will be invaluable, and I welcome it to the bookshelves and to the front bench.

Sir Michael Burton GBE

EDITOR

Peter Feldschreiber

CONSULTANT EDITORS

John Binns
Sarah-Jane Dobson
David Hardstaff

John Johnston
Gareth Morgan

CONTRIBUTORS

John Binns
Louise Bisset
Natalie Coan
Anne Cook
Eleanor Davison
Tom Errington
Joseph Farmer
Tony Fox
Ian Hudson

Emily Jackson
Alison McAdams
Alasdhair McDonald
Mirella Marlow
Leigh-Ann Mulcahy QC
Khadija Rantell (nee Rerhou)
Aimee Riese
Angela Thomas
John Warren

Contents—Summary

<i>Foreword</i>	v
<i>Table of Cases</i>	xix
<i>Table of Legislation</i>	xxvii
<i>List of Abbreviations</i>	xxxvii
1. Introduction	1
<i>Peter Feldschreiber</i>	
2. Clinical Efficacy and Safety: The Concept of Benefit–Risk	27
<i>John Johnston and Khadija Rantell (nee Rerhou)</i>	
3. The Regulation of Biological and other Innovative Medicinal Products	60
<i>Anne Cook, John Johnston, and Louise Bisset</i>	
4. Pharmacovigilance	87
<i>John Warren</i>	
5. Biological Products: Molecular Structure and Function	130
<i>Tony Fox</i>	
6. Health Technology Assessment: Current Issues Impacting on the Regulatory and Legal Framework	158
<i>Mirella Marlow</i>	
7. The Legislation and Regulation of Medical Devices	177
<i>Sarah-Jane Dobson</i>	
8. Regulation of Clinical Trials	195
<i>Emily Jackson and Ian Hudson</i>	
9. Liability in Criminal Law	213
<i>John Binns, Eleanor Davison, David Hardstaff, and Aimee Riese</i>	
10. Liability in Civil Law	257
<i>Leigh-Ann Mulcahy QC and Alison McAdams</i>	
11. Liability in Public Law	311
<i>Leigh-Ann Mulcahy QC and Joseph Farmer</i>	
12. Introduction to Exclusivity Rights	336
<i>Gareth Morgan, Natalie Coan, Tom Errington, and Alasdhair McDonald</i>	
13. Intellectual Property Rights and Medicines	348
<i>Gareth Morgan, Natalie Coan, and Tom Errington</i>	

14. Regulatory Exclusivity Rights and Medicines	382
<i>Gareth Morgan and Alasdhair McDonald</i>	
15. Postscript	411
<i>John Johnston, Angela Thomas, and Peter Feldschreiber</i>	
<i>Index</i>	423

Contents

<i>Foreword</i>	v
<i>Table of Cases</i>	xix
<i>Table of Legislation</i>	xxvii
<i>List of Abbreviations</i>	xxxvii
1. Introduction	
A. The past: 150 BC to thalidomide	1.01
Introduction	1.01
The beginning of modern regulation	1.10
The thalidomide disaster	1.11
The development of modern regulatory standards	1.14
The concept of risk–benefit	1.16
Statutory regulation	1.22
B. The present	1.26
The Licensing Authority	1.26
Committee on Safety of Medicines	1.28
Clinical trials	1.30
Evaluation of safety	1.31
European medicines legislation	1.32
Adverse event reporting	1.33
C. Overview of the current medicines regulatory legislation	1.36
European legislation	1.36
D. The European Medicines Agency	1.39
International harmonisation: ICH	1.41
Development of the current European Medicines Directive	1.42
Definition of medicinal product	1.44
Regulatory data exclusivity	1.45
E. The future	1.47
Role of the patient	1.48
Public private partnerships	1.55
Conduct of clinical trials	1.58
Pharmacogenetics	1.62
Drug device combinations	1.68
Advanced therapy medicinal products	1.71
Herbal medicines	1.75
Health technology assessment and medicines regulation	1.78
F. Medical devices and postscript: Covid-19 and Brexit	1.80
2. Clinical Efficacy and Safety: The Concept of Benefit–Risk	
A. Clinical efficacy	2.01
Introduction	2.01
History of efficacy in clinical trials	2.05

Product development programme	2.18
Evidence of efficacy is obtained by conducting a clinical trial	2.27
Construct of a protocol for a clinical trial	2.32
A claim of clinical efficacy is achieved by a process	2.40
Clinical benefit	2.59
Example of a clinical trial in an 'ideal' setting	2.60
Use of real-world data to make a claim for clinical efficacy	2.62
Example of a clinical trial in a 'real world' setting	2.70
B. Clinical safety	2.75
Introduction	2.75
Initial evidence of safety is obtained by conducting clinical trials	2.79
Collection of safety data	2.83
Initial analysis of safety data	2.86
Recording safety data	2.97
Presentation of safety data	2.103
Collecting safety data is a continuous process	2.107
C. Assessment of benefit–risk balance	2.108
D. Personalised medicine	2.125
E. Addendum: 'big data'	2.132
Introduction	2.132
The European Medicines Agency and 'big data'	2.137
The MHRA and 'big data'	2.140
Rare diseases	2.144
Example of demonstration of efficacy for a rare disease	2.145
Exceptions to the need for a clinical trial to demonstrate efficacy	2.150
3. The Regulation of Biological and other Innovative Medicinal Products	
A. Biological medicinal products	3.01
Introduction	3.01
Quality standards	3.02
Products made using biotechnology	3.03
Products made without biotechnology	3.08
Particular features of biological products	3.09
Manufacturing changes	3.12
B. Biosimilar medicinal products	3.13
Introduction	3.13
Data required for a biosimilar medicinal product	3.19
Challenges for a biosimilar medicinal product	3.27
Changing to a biosimilar medicinal product	3.28
C. Advanced therapy medicinal products (ATMPs)	3.32
Introduction	3.32
The ATMP Regulation	3.35
The Committee for Advanced Therapies	3.41
ATMP manufacture	3.46
ATMP classification	3.52
Challenges encountered in the manufacture of ATMPs	3.58
D. Gene editing	3.62
Introduction	3.62
Four 'families' of gene editors	3.65
CRISPR	3.68
Clinical use of the CRISPR system	3.73

E. Gene therapies	3.76
History of gene therapies	3.76
Strategies for gene therapy	3.83
Ethical issues associated with gene therapies	3.88
F. Cell therapies	3.92
History of cell therapies	3.92
Somatic cell therapy products	3.98
Tissue engineered products	3.100
Unlicensed ATMPs	3.103
Stem cell tourism	3.107
Human embryo stem cells	3.111
G. Regulatory oversight of cell therapies in the UK	3.118
Introduction	3.118
H. Human Fertilisation and Embryology Authority	3.119
I. The Human Tissue Authority	3.123
J. Medicines and Healthcare products Regulatory Agency	3.125
K. The Health Research Authority	3.128
L. Interplay of the regulators	3.130
M. The MHRA Innovation Office	3.137
 4. Pharmacovigilance	
A. Introduction	4.01
Pharmacovigilance and litigation	4.04
Definition	4.07
Defining risk–benefit on certainty, or probability	4.09
The importance of event rates in the risk–benefit assessment	4.15
Reactions, events, and causality	4.19
When does an event rate become a signal?	4.21
Events, causation, and the courts	4.25
Smoking, adverse reactions, and adverse events	4.28
Benefit assessed by reactions or events	4.36
Political, commercial, and public health interests in pharmacovigilance	4.45
Political perspective	4.46
Commercial perspective	4.48
Public health perspective	4.50
History	4.51
Risk–benefit and gambling	4.70
Perception	4.76
B. The licence watershed	4.81
Opening the door and losing control	4.81
The controlled trial and signal dilution	4.84
C. Post-licensing efficacy issues	4.89
Adding efficacy indications	4.89
Questioning efficacy	4.90
The controlled trial resurfaces	4.92
D. Post-licensing safety issues	4.95
Limitations of interpretations	4.95
Case report, case series, databases, and defining concern	4.100
E. Responsibilities, relabelling, and withdrawal	4.113
Regulatory responsibilities, risk management strategy and plan	4.113
Relabelling and withdrawals	4.130

F. Getting the definitive answer	4.136
Medication for high blood pressure	4.138
Lessons from cholesterol	4.140
Rosiglitazone: a case study	4.144
Transparency: Ketek, Trasylol, and Xigris	4.153
G. Conclusions and the future	4.159
Legislation	4.159
Individualisation and genetics	4.160
Collaboration in Europe and worldwide	4.161
Independent assessment	4.163
Practicalities	4.164
Additional guidance	4.174
5. Biological Products: Molecular Structure and Function	
A. What are biological drugs?	5.01
Foil: the orthodox 'small molecule'	5.03
Production of biological products	5.04
B. Types of biological drugs	5.07
C. Proteins (alias polypeptides)	5.09
Primary polypeptide structure	5.09
Secondary, tertiary, and quaternary protein structures	5.13
Protein modification	5.19
Antibodies alias immunoglobulins	5.22
Monoclonal antibodies and their manufacture	5.28
D. Non-enzyme, non-antibody biological therapies	5.37
Cytokines	5.37
Stem cells	5.40
Lymphocyte therapies	5.49
E. DNA, its repair and transcription	5.53
The double helix	5.53
Manufacturing DNA	5.63
Genes	5.65
DNA outside the cell nucleus	5.69
Gene therapies and their vectors	5.70
F. RNA, translation and post-translational modification of proteins	5.78
RNA	5.78
Antisense and short interfering RNA (siRNA)	5.85
G. Testing for drug genotoxicity and carcinogenicity	5.88
H. Clinical hazard: why do biological drug products differ from small molecules?	5.98
The concept of the equilibrium	5.98
Clinical implications	5.101
I. Biological products and big data	5.103
6. Health Technology Assessment: Current Issues Impacting on the Regulatory and Legal Framework	
A. Introduction	6.01
B. Introduction to Health Technology Assessment	6.02
C. National Institute for Health and Care Excellence	6.06
Unwarranted variation in access to treatment	6.06

Establishment of the National Institute for Clinical Excellence (NICE)	6.07
NICE principles	6.13
D. How NICE appraises technologies	6.20
Timing and relationship of NICE technology appraisals to regulatory process for medicines	6.20
Approach to cost effectiveness	6.25
The reference case	6.27
Process for developing technology appraisals guidance	6.33
Rationale for a dedicated approach for medical technologies and diagnostics	6.48
Approach to guidance on non-medicines technologies	6.51
Pre-publication process	6.59
How the NHS implements NICE recommendations	6.65
E. Patient and public involvement in the work of NICE	6.68
7. The Legislation and Regulation of Medical Devices	
A. Legislation	7.01
EU	7.01
UK	7.04
Overview of legislation	7.08
B. Key statutory concepts	7.16
Scope	7.17
C. Regulation	7.47
Regulators	7.47
Other relevant bodies	7.51
Notified Bodies and Approved Bodies	7.53
Main regulatory functions	7.63
D. The future	7.84
8. Regulation of Clinical Trials	
A. European regulation of clinical trials	8.01
B. The ethics of clinical trials	8.11
Consent	8.13
Risk–benefit	8.15
Randomised controlled trials and the use of placebos	8.17
The ethics of pandemic research	8.19
C. Overview of the main provisions of the Clinical Trials Directive	8.21
D. GCP Directive	8.23
E. GMP Directive	8.24
F. Other aspects of the UK regulations	8.26
Sponsorship responsibilities	8.26
Timelines	8.27
Amendments	8.28
G. Assessment of applications by competent authority	8.29
H. EudraCT database	8.30
I. EudraVigilance database	8.31
J. First-in-human studies	8.32
K. Paediatric trials	8.33
L. Publication of clinical trials	8.36
M. Overview of the Clinical Trials Regulation 2014	8.39
N. The authorisation process	8.45

O. Other aspects of the CTR	8.53
Notifications	8.55
Safety reporting requirements	8.56
Transparency	8.57
P. Conclusion	8.58
9. Liability in Criminal Law	
A. Introduction	9.01
B. The broader relevance of the criminal law	9.05
Offences against the person	9.05
Inchoate offences	9.17
C. The controlled drugs regime	9.19
Controlled drugs offences	9.19
The Misuse of Drugs Regulations 2001	9.27
D. Corporate and financial crime	9.28
Corporate criminal liability	9.28
Liability for officers of an offending corporate entity	9.31
Intellectual property offences, competition offences, etc	9.32
Money laundering	9.35
Fraud	9.41
Corporate manslaughter	9.42
Bribery	9.44
Data protection offences	9.46
E. Criminal law aspects of the regulatory regime	9.47
The basis for the offence-creating provisions	9.47
Offences under the Medicines Act 1968	9.51
Medical devices: offences	9.55
Offences under the Human Medicines Regulations 2012	9.56
F. The criminal enforcement process	9.74
Criminal investigation	9.74
Proceeds of crime investigations	9.86
Non-prosecution disposals	9.92
Prosecution and outcome	9.93
Interaction with professional disciplinary and debarment procedures	9.102
G. Medicinal cannabis	9.103
Cannabis and its uses	9.103
Cannabis and the law	9.106
Cannabis-based products for medicinal use in humans	9.123
Cannabidiol	9.137
The Home Office licensing process	9.147
10. Liability in Civil Law	
A. Introduction	10.01
B. Liability at common law	10.04
General	10.04
Liability in negligence	10.05
C. Liability under the consumer protection legislation	10.16
Genesis of the legislation	10.16
Judicial consideration of the legislation	10.20
Purpose of the legislation	10.28

Key provisions of the Product Liability Directive	10.36
Interpretation of the Directive	10.37
Defences	10.57
Article 7(a): the uncirculated products defence	10.58
Article 7(b): the subsequent defects defence	10.60
Article 7(c): the non-economic purpose defence	10.61
Article 7(d): the mandatory regulations defence	10.62
Article 7(e): the development risks defence	10.64
Article 7(f): components defence	10.69
Contributory fault	10.70
Damage	10.71
Limitation for claims under the consumer protection legislation	10.74
Contribution	10.81
The future of the Directive	10.83
D. Specific liabilities of those involved in medicines	10.84
Manufacturers	10.84
Supply chains	10.86
Importers	10.87
Doctors and other prescribers	10.88
Dispensing pharmacists	10.89
Regulators	10.92
Health authorities/NHS trusts	10.93
E. Causation	10.94
Introduction	10.94
The Courts' approach to causation	10.99
F. Liability of regulators	10.123
Introduction	10.123
Regulatory bodies in relation to pharmaceuticals	10.124
Regulatory bodies in relation to medical devices	10.128
Principles of civil liability	10.129
Case law relating to regulators	10.148
Circumstances in which a claim might be brought	10.157
Conclusion	10.167
G. Other statutes relevant to liability for medicines	10.168
Vaccine Damage Payments Act 1979	10.168
Congenital Disabilities (Civil Liability) Act 1976	10.169
Other	10.170
11. Liability in Public Law	
A. Introduction	11.01
B. Public law challenges	11.02
Judicial review	11.03
Claims under the Human Rights Act 1998	11.17
C. Specific examples of public law liability	11.26
Provision of medicines	11.26
Other policy and guidance	11.44
The Medicinal Products Directive	11.52
The Medical Devices Directive	11.60

12. Introduction to Exclusivity Rights	
A. Intellectual property and medicinal products	12.01
What are intellectual property rights?	12.01
Intellectual property rights are proprietary	12.04
Intellectual property rights are negative/exclusory rights	12.05
Intellectual property rights are of a limited duration	12.06
Intellectual property rights are of restricted scope	12.08
National and international in character	12.11
How do intellectual property rights apply to medicines?	12.12
Patents	12.14
Trade marks	12.17
Copyright	12.22
Design rights	12.27
Confidential information	12.30
B. Regulatory exclusivities and life sciences products	12.33
What are regulatory exclusivities?	12.33
Data and market exclusivity	12.36
Orphan market exclusivity	12.40
Paediatric exclusivities	12.46
13. Intellectual Property Rights and Medicines	
A. Introduction	13.01
B. Patents	13.02
What is a patent and what can it protect?	13.02
Term	13.08
Legislative framework	13.10
Requirements for patentability	13.18
Novelty	13.20
‘Use’ inventions	13.27
Inventive step	13.30
Obviousness	13.33
Sufficiency	13.39
Industrial application	13.45
Exclusions	13.47
Biotech Directive exclusions	13.48
Exceptions	13.50
Overview of application procedure, timing, and costs	13.52
Application procedure	13.55
Renewal fees	13.59
Infringement/Construction	13.61
Infringement by variants	13.66
C. Supplementary protection certificates	13.70
The nature of SPCs	13.70
How do you get one?	13.72
What is the duration of an SPC?	13.75
Exemptions from infringement	13.78
Litigation	13.80
The future	13.82
D. Trade marks and passing off	13.84
What is a trade mark?	13.84

How are they obtained?	13.88
What is the term?	13.91
What can be protected?	13.92
Naming of pharmaceuticals	13.93
Parallel trade	13.99
Trade mark enforcement	13.108
Passing off	13.110
E. Case study	13.115
14. Regulatory Exclusivity Rights and Medicines	
A. Data exclusivity	14.02
The reference medicinal product	14.04
‘Full’ marketing authorisation applications	14.09
Data and market exclusivity and abridged applications	14.13
The ‘+1’ market exclusivity right	14.18
Abridged applications	14.20
B. The global marketing authorisation	14.25
Bridging data and data exclusivity under Article 10(3)	14.25
The global marketing authorisation	14.29
New active substance	14.35
Article 10(5) and an additional year of exclusivity	14.42
Orphan market exclusivity	14.46
Defining the condition	14.52
Article 3 criteria	14.56
Economic criteria	14.60
‘[T]here must exist no satisfactory method of diagnosis, treatment or prevention of the condition that has been authorised in the EU’	14.62
‘[I]f such method exists, the medicinal product must be of significant benefit to those affected by the condition’	14.64
Court treatment of orphan exclusivity	14.68
Similar medicinal product	14.78
Derogations	14.90
Reduction of duration of orphan exclusivity	14.97
Paediatric exclusivity	14.98
Inter-operation of data, market, orphan, and paediatric exclusivities	14.107
15. Postscript	
A. Introduction	15.01
B. Regulation after Brexit	15.02
Introduction	15.02
Medicinal products	15.04
Clinical trials	15.15
Medical devices	15.19
C. The impact of the Covid-19 pandemic	15.27
D. The Independent Medicines and Medical Devices Safety Review 2020	15.35
Introduction	15.35
Conduct of the Review	15.39
Findings of the Review	15.46
Recommendations and actions for improvement	15.47
Publication of the Review	15.49

E. The UK Infected Blood Inquiry	15.50
Introduction	15.50
The Chair and the Inquiry Team	15.53
Expert groups	15.57
Core participants	15.60
Hearings and information for witnesses	15.64
Addendum	15.69
<i>Index</i>	423

Table of Cases

AUSTRALIA

Merck Sharpe & Dohme (Australian) Pty Ltd v Peterson [2011] FCAFC 128	10.10, 10.107
Thompson v Johnson & Johnson Pty Ltd, [1992] 3 Med LR 148, Supreme Court of Victoria.	10.09

CANADA

Buchan v Ortho Pharmaceuticals (Canada) Ltd, (1986) 25 DLR (4th) 568.	10.09
---	-------

COURT OF JUSTICE OF THE EUROPEAN UNION

Actavis Group PTC EHf and Actavis UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG (Case C-577/13) ECLI:EU:C:2015:165	13.81
Actavis Group PTC EHf and Actavis UK Ltd v Sanofi (Case C-433/12) ECLI:EU:C:2013:156	13.81
AHP Manufacturing BV (Case C-181/95) ECLI:EU:C:1997:32	13.81
Andrea Francovich and Danila Bonifaci and others v Italy (Joined Cases C-6/90 and 9/90) ECLI:EU:C:1991:428	11.54
Andreas Kainz v Pantherwerke AG (Case C-45/13) ECLI:EU:C:2014:7	10.59
Arne Forsgren (Case C-631/13) ECLI:EU:C:2015:13	13.81
Astellas Pharma GmbH (Case C-557/16) ECLI:EU:C:2018:181	11.57, 14.08
Bayer Cropscience AG (Case C-11/13) ECLI:EU:C:2014:2010	13.81
Bayer Intellectual Property GmbH v kohlpharma GmbH (Case C-204/20)	13.107
Biogen Inc v Smithkline Beecham Biologicals SA (Case C-181/95) ECLI:EU:C:1997:32	13.81
Boston Scientific Limited (Case C-527/17) ECLI:EU:C:2018:867	13.81
Boston Scientific Medizintechnik GmbH v AOK Sachsen-Anhalt Die Gesundheitskasse and Betriebskrankenkasse RWE (Case C-503/13) ECLI:EU:C:2015:148	10.27, 10.119
Bristol-Myers Squibb v Paranova A/S (Joined Cases C-427/93, C-429/93, and C-436/93) ECLI:EU:C:1996:282	13.103
Bristol-Myers Squibb Pharma v Commission and European Medicines Agency (Case T-329/16) ECLI:EU:T:2018:878	14.76
Commission v Spain (Case C-88/07) ECLI:EU:C:2009:123	11.59
Commission v United Kingdom (Case C-300/95) ECLI:EU:C:1997:255	10.64, 10.68
Declan O'Byrne v Sanofi Pasteur MSD Ltd and Sanofi Pasteur SA (Case C-127/04) ECLI:EU:C:2006:93	10.58, 10.85
Eli Lilly v Genentech (Case C-239/19) ECLI:EU:C:2019:687	13.74
Eli Lilly v Human Genome Sciences (Case C-493/12) ECLI:EU:C:2013:835	13.81
Elisabeth Schmitt v TÜV Rheinland LGA Products GmbH (Case C-219/15) ECLI:EU:C:2017:128	10.156
European Medicines Agency v Shire Pharmaceuticals Ireland Ltd (Case C-359/18 P) ECLI:EU:C:2019:639	14.75
Generics (UK) Ltd v Synapsech (Case C-427/09) ECLI:EU:C:2011:520	13.81, 14.04–14.06
Glaxosmithkline Biologicals SA and Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG v Comptroller General of Patents, Designs and Trade Marks (Case C-210/13) ECLI:EU:C:2013:762	13.81
GMP-Orphan v Commission (Cuprior) (Case T-733/17) ECLI:EU:T:2019:334	14.67, 14.76
Hecht-Pharma GmbH v Hohenzollern Apotheke (Case C-276/15) ECLI:EU:C:2016:801	11.55

Henning Veedfald v Arhus Regional Authority (Case C-203/99) ECLI:EU:C:2001:258	10.36, 10.38, 10.58
Hexal AG v European Medicines Agency (Case T-459/18) ECLI:EU:T:2021:86	14.41
HLH Warenvertriebs GmbH v Germany (Joined cases C-211/03, C-299/03 and C-316/03 to C-318/03) ECLI:EU:C:2005:370	11.53
Ker-Optika bt v ANT SZ Del-dunantuli Regionalis Intezete (Case C-108/09) ECLI:EU:C:2010:725	11.59
Laboratoires CTRS v Commission (Case T-452/14) ECLI:EU:T:2015:373	14.69
María Victoria González Sánchez v Medicina Asturiana Sa (Case C-183/00) ECLI:EU:C:2002:255	10.19
Marleasing SA v La Comercial Internacional de Alimentacion SA (Case C-106/89) ECLI:EU:C:1990:395	10.19
Massachusetts Institute of Technology (MIT) (Case C-431/04) ECLI:EU:C:2006:291	13.81
Medac Gesellschaft für klinische Spezialpräparate mbH v Commission (Case T-549/19) ECLI:EU:T:2020:444	14.76
Medeva BV (Case C-322/10) ECLI:EU:C:2011:773	13.81
Merck Parties v Abacus Medicine A/S, Paranova Danmark and another (Case C-224/20)	13.107
Merck Sharp & Dohme Corporation (Case C-125/10) ECLI:EU:C:2011:812	13.81
Merck Sharp & Dohme Corporation (Case C-567/16) ECLI:EU:C:2017:948	13.81
MSD Sharp & Dohme GmbH v Merckle GmbH (Case C-316/09) ECLI:EU:C:2011:275	11.59
N W and Others v Sanofi Pasteur MSD SNC (Case C-621/15) ECLI:EU:C:2017:484	10.118
Novartis Europharm Ltd v Commission (Case T-269/15) ECLI:EU:T:2019:361	14.96
Novartis Pharma GmbH v Abacus Medicine A/S (Case C-147/20)	13.107
Nycomed Danmark ApS v European Medicines Agency (Case T-52/09) ECLI:EU:T:2011:738	14.98
Oliver Brüstle v Greenpeace eV (Case C-34/10) ECLI:EU:C:2011:669	13.12
Orifarm v Merck (Joined Cases C-400/09 and C-207/10)	13.104
Pari Pharma GmbH v European Medicines Agency (Case T-235/15) ECLI:EU:T:2018:65	14.95
Pharmaceutical Works Polpharma S.A. v European Medicines Agency (Case T-611/ 18) ECLI:EU:T:2021:241	14.41
R v The Licensing Authority established by the Medicines Act 1968 (acting by The Medicines Control Agency), ex parte Generics (UK) Ltd, The Wellcome Foundation Ltd and Glaxo Operations UK Ltd and Others (Case C-368/96) ECLI:EU:C:1998:583	14.31
R (Approved Prescription Services Ltd) v Licensing Authority (Case C-36/03) ECLI:EU:C:2004:781	11.56, 14.31
R (Novartis Pharmaceuticals UK Ltd) v Licensing Authority (Case C-106/01) ECLI:EU:C:2004:245	11.56, 14.31
R (Association of the British Pharmaceutical Industry) v Medicines and Healthcare Products Regulatory Agency (Case C-62/09) ECLI:EU:C:2010:219	11.59
Royalty Pharma Collection Trust (Case C-650/17) ECLI:EU:C:2020:327	13.81, 13.118
Santen SAS (Case C-673/18) ECLI:EU:C:2020:531	13.81
Seattle Genetics Inc (Case C-471/14) ECLI:EU:C:2015:659	13.81
Shire Pharmaceuticals Ireland v European Medicines Agency (Case T-80/16) ECLI:EU:T:2018:165	14.74–14.75
Skov AEG v Bilka Lavprisivarehus As (Case C-402/03) ECLI:EU:C:2006:6	10.19
Synthon BV v Merz (Case C-195/09) ECLI:EU:C:2011:518	13.81
Teva v Commission and European Medicines Agency (Case T-628/19) (Information not available)	14.41
Teva Pharma BV and Teva Pharmaceuticals Europe BV v European Medicines Agency (Case C-138/15 P) ECLI:EU:C:2016:136	14.70–14.73
Teva Pharma BV and Teva Pharmaceuticals Europe BV v European Medicines Agency (Case T-140/12) ECLI:EU:T:2015:41	14.70–14.73
Teva UK Ltd v Gilead Sciences Inc (Case C-121/17) ECLI:EU:C:2018:585	13.81
Viridis Pharmaceutical Limited (Case C-688/17 P) ECLI:EU:C:2019:722	13.98
Yeda Research and Development Company Ltd (Case C-518/10) ECLI:EU:C:2011:779	13.81

EFTA COURT OF JUSTICE

Grund, Elli-og Hjukrunarheimili v Icelandic Medicines Agency (Lyfjastofnun) (Case E-7/11)	11.59
--	-------

EUROPEAN COURT OF HUMAN RIGHTS

Aleksanyan v Russia (2011) 52 EHRR 18	11.38
Bataliny v Russia, Application No 10060/07, 23 July 2015	11.38, 11.41
Dodov v Bulgaria (2008) 47 EHRR 41	11.34
Fedulov v Russia (2020) 70 EHRR 23	11.36
Herczegfalvy v Austria (1993) 15 EHRR 437	11.40
Hristozov v Bulgaria Application Nos 47039/11 and 358/12, 29 April 2013	11.37
Jalloh v Germany (2007) 44 EHRR 32	11.41
Khudobin v Russia, (2009) 48 EHRR 22	11.38
Lopes de Sousa Fernandes v Portugal (2018) 66 EHRR 28	11.34
Nitecki v Poland Application No 65653/01, 21 March 2002	11.35
Pentiacova v Moldova (2005) 40 EHRR SE23	11.36
Scialacqua v Italy (1998) 26 EHRR 164 (Commission Decision)	11.34
Sentges v Netherlands Application No 27677/ 02, 8 July 2003	11.43
Tysiac v Poland (2007) 45 EHRR 42	11.42
Vasileva v Bulgaria, Application No 23796/ 10, 12 September 2016	11.42, 11.43
Wenner v Germany (2017) 64 EHRR 19	11.38
X v Finland, Application No 34806/04, 19 November 2012	11.42

NETHERLANDS

Exjade (deferasirox) case, District Court of The Hague (PI Judge Brinkman), 29 September 2020, KG ZA 20-605	14.105
Orion Corporation v the Medicines Evaluation Board case UTR/ 18/ 1103	14.07

UNITED KINGDOM

A v National Blood Authority (No 1) [2001] 3 All ER 289; [2001] Lloyd's Rep Med 187; (2001) 60 BMLR 1	10.20, 10.28, 10.31, 10.39, 10.45, 10.48, 10.49, 10.55, 10.61, 10.64
AB v Ministry of Defence [2012] UKSC 9; [2012] 2 WLR 643, SC	10.115
ABK Co Music and Records Inc v Music Collection International Limited [1995] RPC 657	12.11
Abouzaid v Mothercare (UK) Ltd, The Times, 20 February 2001	10.45, 10.66
Actavis v ICOS [2019] UKSC 15	13.36–13.37
Actavis UK Limited and others v Eli Lilly and Company [2017] UKSC 48	12.10
Adomako [1995] 1 AC 171	9.12
Aer Lingus Plc v Gildacraft Ltd [2006] EWHC Civ 4; [2006] 2 All ER 290, CA	10.14
Allergan v Aspire and Accord [2019] EWHC 1085	13.36
Andrews [2002] EWCA Crim 3021; [2003] Crim LR 477	9.11
Anns v Merton London Borough Council [1978] AC 728, HL	10.136
Associated Provincial Picture Houses Ltd. v Wednesbury Corporation [1948] 1 KB 223	11.53
Badger v Ministry of Defence [2005] EWHC 2941	10.104
Bailey and others v GlaxoSmithKline [2019] EWCA Civ 1924	10.25, 10.26, 10.35
Bank Mellat v Her Majesty's Treasury (No 2) [2014] AC 700	11.12
Barclays Bank plc v Fairclough Buildings Ltd (No 2) [1995] IRLR 605, AC	10.11
Barrett v Enfield LBC [2001] 2 AC 550, HL	10.07
Biogen Inc v Medeva plc [1997] RPC 49	13.43
Blackbay Ventures Ltd v Secretary of State for Health [2012] EWHC 2635 (Admin)	11.59
Blackmore v Department for Communities and Local Government [2017] EWCA Civ 1136; [2018] QB 471	10.107

Bolam v Friern Hospital Management Committee [1957] 1 WLR 582	1.02
Bolton MDC v Secretary of State for the Environment [1995] 1 WLR 1176	11.16
Bonthrone v Secretary of State for Scotland (1987) SLT 34	10.07
Bristol-Myers Squibb v Baker Norton Pharmaceuticals [2001] RPC 1	13.29
British Acoustic Films, 53 RPC 221	13.35
British Westinghouse v Braulik (1910) 27 RPC 209	13.38
Brugger v Medic-Aid Ltd (No 2) [1996] RPC 635	13.36
Burton v Islington Health Authority [1993] QB 204, CA	10.169
Bux v Slough Metals Ltd [1973] 1 WLR 1358, CA	10.09
Chester v Afshar [2005] 1 AC 134	10.120–10.122
Cipla Ltd v Glaxo Group Ltd [2004] EWHC 477	13.38
Coco v AN Clark (Engineers) Ltd [1968] FSR 415	12.30
Conor Medsystems Inc v Angiotech Pharmaceuticals Inc [2008] UKHL 49	13.32, 13.36
Danns v Department of Health (1995) 25 BMLR 121	10.04, 10.146
Donoghue v Stevenson [1932] AC 562, HL	10.05, 10.06
Dwyer v Roderick (1983) 127 SJ 806	10.04
E Mishan & Sons, Inc (t/a Emson) v Hozelock Ltd and others [2019] EWHC 991 (Pat)	13.21
Eisai Ltd v NICE [2008] EWCA Civ 438	11.46, 11.47
Eli Lilly v Actavis UK Ltd and Ors [2017] UKSC 48	13.66
Eli Lilly v Genentech [2019] EWHC 388 (Pat)	13.74
Eli Lilly v Human Genome Sciences Inc [2010] EWCA Civ 33	13.32
Exjade (deferasirox) case, UK Patents Court matter HP- 2020-000023	14.105
Fairchild v Glenhaven [2003] 1 AC 32, HL	10.106, 10.111–10.116
Folding Attic Stairs Ltd v The Loft Stairs Company Ltd [2009] EWHC 1221 (Pat)	13.21
Fomento v Mentmore (1956) RPC 87	13.21
Forsikringsaktieselskapet Vesta v Butcher [1989] AC 852; [1989] 1 All ER 402, HL	10.11
Gee v DePuy International Limited (Gee) [2018] EWHC 1208, QB	10.23, 10.26, 10.35, 10.56, 10.68, 10.97, 10.99
General Tire v Firestone & Rubber [1972] RPC 457	13.22, 13.34, 13.35
Glaxo Group Ltd v Dowellhurst Ltd and other cases (Nos 2 and 3) [2004] EWCA Civ 129	13.103, 13.111
Glaxo Wellcome UK Ltd (t/a Allen & Hanburys) and another v Sandoz Ltd [2017] EWCA Civ 335	13.109, 13.112–13.113, 13.119, 13.121
Gorringe v Calderdale Metropolitan Borough Council [2004] UKHL 15; [2004] 1 WLR 1057	10.136
Gregg v Scott [2005] 2 WLR 268	10.115
Griffiths v Arch Engineering Co (Newport) Ltd [1968] 3 All ER 217	10.06
H v Alexandria Hospital [1990] Med LR 297	10.09, 10.166
H v Schering Chemicals Ltd [1983] 1 WLR 143	10.101
Hallen v Brabantia [1991] RPC 195	13.36
Harvard/OncoMouse [1991] EPOR 525 (Exam)	13.49
Hedley Byrne & Co Ltd v Heller & Partners Ltd [1964] AC 465	10.141–10.144
Heneghan v Manchester Dry Docks Ltd [2016] EWCA Civ 86; [2016] 1 WLR 2036	10.107
Henvey v HM Advocate [2005] HCJAC 10	9.119
Hodgson v Imperial Tobacco Ltd, Unreported, 9 January 1999	10.109
Holmes v Ashford [1950] 2 All ER 76, CA	10.88
Hotson v East Berkshire AHA [1987] AC 750, HL	10.105
Hope & Reay v British Nuclear Fuels [1994] Env LR 320, QB	10.101
Horne-Roberts v Smithkline Beecham plc (2002) 1 WLR 1662; (2002) 65 BMLR 79, CA	10.74
Horton v Evans & Lloyds Pharmacy, (2007) 94 BMLR 60; (2007) PNLR 17	10.91
Human Genome Sciences Inc v Eli Lilly and Company [2011] UKSC 51	13.17, 13.45
Hurley v Dyke [1979] RTR 265, HL	10.06
Hyaltech Ltd, Petitioners, 2009 SLT 92	11.60
Independent Broadcasting Authority Ltd v EMI Electronics Ltd (1981) 14 BLR 1	10.09

International Energy Group Ltd v Zurich [2015] UKSC 33; [2016] AC 509	10.115
KCI Licensing Inc and another v Smith & Nephew PLC and anor [2010] EWHC 1487	13.35
Kent v Griffiths [2000] 2 All ER 474	10.07
Kinnear v DHSS (1984) 134 NLJ 886	10.07
Kirin-Amgen Inc and others v Hoechst Marion Roussel Limited and others [2004] UKHL 46	13.42
Kubach v Hollands [1937] 3 All ER 9	10.88
Lily Icos Ltd v Pfizer Ltd [2001] FSR 201	13.34
Limbuela v Secretary of State for the Home Department [2005] 3 WLR 1014	11.39
Loveday v Renton & Wellcome Foundation Ltd, 29 March 1988; The Times, 31 March 1988, QB	10.95
McTear v Imperial Tobacco Ltd, [2005] CSOH 69; The Times, 14 June 2005	10.101, 10.104
Medimmune v Novartis [2011] EWHC 1669	13.43
Mentor v Hollister [1994] RPC 7	13.41
Meridian Global Funds Management Asia Ltd v The Securities Commission [1995] UKPC 5, 26 June 1995	9.28
Merrell Dow Pharmaceuticals Inc v H N Norton & Co Ltd [1996] RPC 76	13.24
Misra [2004] EWCA Crim 2375; [2005] 1 Cr App R 21	9.12
Multiple Claimants v Sanifo-Synthelabo Ltd and another [2007] EWHC 1860	10.169
N and Others v UK Medical Research Council and Secretary of State for Health [1996] Med LR 309	10.153
National Aids Trust v NHS Commissioning Board (NHS England) [2017] 1 WLR 1477	11.27
Novartis v Johnson & Johnson [2010] EWCA Civ 1039	13.41
Novartis Grimsby Ltd v Cookson [2007] EWCA Civ 1261	10.107
O'Byrne v Aventis Pasteur SA [2007] EWCA Civ 939	10.74
Optident Ltd and another v Secretary of State for Trade & Industry and Secretary of State for Health (2001) 61 BMLR 10	11.60
Orion Corp v Secretary of State for Health and Social Care [2019] EWHC 689 (Admin)	11.57, 14.07, 14.08
Oxford v Moss [1978] 68 Cr App R 183	12.30
Poole Borough Council v GN and another [2019] UKSC 25; [2020] AC 780	10.134, 10.137, 10.142, 10.144
Pozzoli Spa v BDMO SA and another [2007] EWCA Civ 588	13.33
Qualcomm v Nokia [2008] EWHC 239	13.21
R (Actegy Ltd) v Advertising Standards Authority Ltd [2019] EWHC 2374 (Admin)	11.60
R (Otley) v Barking and Dagenham NHS Primary Care Trust [2007] EWHC 1927 (Admin)	11.31
R v Cambridge Health Authority, ex p B [1995] 1 WLR 898, CA	11.28, 11.29
R v Champ [1981] 5 WLUK 128; (1981) 73 Cr App R 367; [1982] Crim LR 108	9.119
R v Chapman [2017] EWCA Crim 1743	9.114
R (M) v Croydon LBC [2012] 1 WLR 2607	11.16
R v Deputy Governor of Parkhurst Prison, ex p Hague [1992] 1 AC 58.	10.04
R (B) v Dr SS (Responsible Medical Officer Broadmoor Hospital) [2005] EWHC 1936 (Admin)	11.40
R v Gumbs (1926) 19 Cr App R 74	9.101
R (Beer) v Hampshire Farmers Markets Ltd [2004] 1 WLR 233	11.08
R (JBOL Ltd) v Health Protection Agency [2011] EWHC 236	11.51
R (Richmond Pharmacology Ltd) v Health Research Authority [2015] EWHC 2238 (Admin)	11.51
R (Hidden Hearing Ltd) v Hearing Aid Council [2009] EWHC 63 (Admin)	11.51
R v Inland Revenue Commissioner, ex p National Federation of Self Employed and Small Businesses Ltd [1982] AC 617	11.07
R v Insurance Ombudsman Bureau ex p Aegon Life Assurance Ltd [1994] CLC 88	11.08
R (Holmcroft Properties Ltd) v KPMG LLP [2016] EWHC 323 (Admin); [2018] EWCA Civ 2093	11.08
R v Lambert [2001] UKHL 37; [2002] 2 AC 545	9.119

R v Licensing Authority and Others, ex p Merck Sharp & Dohme Ltd [2005]	
EWHC 710 (Admin)	14.31
R v Licensing Authority, ex p Novartis Pharmaceuticals UK Ltd (30 March 2000)	11.56
R (H) v Mental Health Review Tribunal [2007] EWHC 884 (Admin)	11.42
R (British Homeopathic Association) v National Health Service Commissioning Board [2018] EWHC 1359 (Admin)	11.51
R (Servier Laboratories Limited) v National Institute for Health and Clinical Excellence [2010] EWCA Civ 346	11.44
R (Boeinger Ingelheim Ltd) v NHS Commissioning Board [2016] EWHC 1557 (Admin)	11.31
R (Bayer Plc) v NHS Darlington CCG [2020] EWCA Civ 449	11.51
R (S (A Child)) v NHS England [2016] EWHC 1395 (Admin)	11.31
R (SB) v NHS England [2017] EWHC 2000 (Admin)	11.31, 11.50
R (Cotter) v NICE [2020] EWCA Civ 1037	11.50
R (Bristol-Myers Squibb Pharmaceuticals Ltd) v NICE [2009] EWHC 2722 (Admin)	11.47
R (Fraser) v NICE [2009] EWHC 452	11.48
R (Servier Laboratories Ltd) v NICE [2010] EWCA Civ 346	11.49
R v North and East Devon Health Authority, ex p Coughlan [2001] QB 213	11.27, 11.29
R v North Derbyshire Health Authority, ex p Fisher [1997] 8 Med LR 327	10.07, 10.146
R (Condliff) v North Staffordshire Primary Care Trust [2012] 1 All ER 689	11.42
R v North West Lancashire Health Authority, ex p A [2000] 1 WLR 977	11.29–11.30
R v Panel on Takeovers and Mergers, ex p Datafin [1987] QB 815	11.03
R (A) v Partnerships in Care [2002] 1 WLR 2610	11.17
R (Archer) v Revenue and Customs Commissioners [2019] 1 WLR 6355	11.05
R (Murphy) v Salford Primary Care Trust [2008] EWHC 1908 (Admin)	11.31
R v Secretary of State, ex p Walker (1992) 3 BMLR 32	10.04, 10.130
R (Blue Bio Pharmaceuticals Ltd) v Secretary of State for Health [2016] EWCA Civ 554	11.53
R (Napp Pharmaceuticals Ltd) v Secretary of State for Health [2016] EWHC 1982 (Admin)	11.56, 14.14
R (National Association of Health Stores) v Secretary of State for Health [2005] EWCA Civ 154	11.51
R v Secretary of State for Health, ex p Pfizer Ltd [2002] EWCA Civ 1566	11.30
R (Roche Registration Ltd) v Secretary of State for Health [2016] 4 WLR 46	11.59
R (Teva BV) v Secretary of State for Health [2018] EWHC 228 (Admin)	11.58
R (Good Law Project Ltd) v Secretary of State for Health and Social Care [2019] EWCA Civ 1211	11.59
R v Secretary of State for the Home Department, ex p Doody [1994] 1 AC 531	11.13
R (Mohammed) v Secretary of State for the Home Department [2013] EWHC 1940 (Admin)	11.51
R v Secretary of State for Social Services, ex p Hincks [1980] 1 BMLR 93	11.27
R (Ann Marie Rogers) v Swindon NHS Primary Care Trust [2006] 1 WLR 2649	11.31, 11.39
R (Ross) v West Sussex Primary Care Trust [2008] EWHC 2252 (Admin)	11.31
Ralph v Yamaha Motor Co Ltd, 5 July 1996, unreported	10.09
Regeneron v Kymab [2018] EWCA Civ 671	13.44
Regeneron and Bayer v Genentech [2013] EWCA Civ 93	13.32
Richardson v LRC Products Ltd (2001) 59 BMLR 185	10.52, 10.67
Robinson v Chief Constable of West Yorkshire [2018] UKSC 4; [2018] AC 736	10.134–10.138
Rockwater v Technip [2004] EWCA Civ 381	13.34
Rose [2017] EWCA Crim 1168 [2018] QB 328	9.13
Ross v Secretary of State for Scotland [1990] Med LR 235	10.07, 10.146
Sarah Jane Wilson and ors v (1) Bayer Pharma AG, (2) Schering Health Care Ltd, (3) Aventis Pharma Ltd and (4) Secretary of State for Health and Social Care	10.152
Savage v South Essex Partnership NHS Foundation Trust [2009] 1 AC 681	11.34
Sayers and others v Smithkline Beecham plc and others [2004] EWHC 1899, QB	10.95
Sharma v Brown Antoine [2017] 1 WLR 780	11.04
Sienkiewicz v Greif (UK) Ltd [2011] UKSC 10; [2011] 2 AC 229, SC	10.106, 10.108

Smith (by her mother and next friend) v Secretary of State for Health [2002]	
Lloyd's Rep Med 305.	10.04, 10.130, 10.145, 10.149–10.151
Speciality European Pharma Ltd v Doncaster Pharmaceuticals Group Ltd and Anor [2015]	
EWCA Civ 54.	13.104
Spring v Guardian Assurance plc [1995] 2 AC 296, HL.	10.142
Stovin v Wise [1996] UKHL 15; [1996] AC 923.	10.136
Synthon BV v Smithkline Beecham plc [2005] UKHL 59.	13.23, 13.24
Taylor v Rover Co Ltd [1966] 2 All ER 181.	10.09
Technograph Printed Circuits Ltd v Mills & Rockley (Electronics) Ltd [1972] RPC 346.	13.36
Tesco Supermarkets Ltd v Natrass [1972] AC 153.	9.28
Three Rivers District Council v Bank of England (No 3) [2003] 2 AC 1.	10.147
Three Rivers District Council and ors v Bank of England [2006] EWHC 816 (Comm); [2006]	
5 Costs LR 714.	10.147
Thompson v Smiths Shiprepairers Ltd, [1984] QB 405.	10.09
Vacwell Engineering Co v BDH Chemicals [1971] 1 QB 88.	10.09
Wilkes v DePuy International Limited, [2016] EWHC 3096; [2017] 3 All ER 589, QB. ...	10.21, 10.24,
	10.26, 10.35, 10.46, 10.50, 10.56, 10.63, 10.97, 10.116
Wilson v Beko [2019] EWHC 3362, QB.	10.75
Windsurfing v Tabur Marine [1985] RPC 59.	13.33
Winward v TVR Engineering Ltd, 4 March 1986, unreported, QB.	10.09
Worsley v Tambrands Ltd [2000] PIQR P95.	10.09, 10.54
Wright v Dunlop Rubber Co Ltd, (1973) 13 KIR 250.	10.09
X (minors) v Bedfordshire County Council [1995] 2 AC 633, HL.	10.07
XYZ v Schering Health Care Limited [2002] EWHC 1420.	10.51, 10.65, 10.95, 10.107, 10.116
YL v Birmingham City Council [2007] 1 AC 95.	11.17

UNITED STATES

Herskovits v Group Health Cooperative of Puget Sound (1983) P 2d 474, Supreme	
Court of Washington.	10.108
Hymowitz v Eli Lilly & Co 541 NYS 2d 941 (Ct App, 1989).	10.117
Sindell v Abbott Laboratories, 607 P 2d 924 (Cal, 1980).	10.117

Table of Legislation

Tables are indicated by *t* following the paragraph number.

EUROPEAN UNION

Treaties

Czech accession Treaty.....	14.07
EC Treaty	
Art 28.....	11.59
Art 249.....	10.19
Treaty on the Functioning of the European Union (TFEU)	
Art 34.....	11.59
Art 36.....	11.59

Regulations

Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products [2000]	
OJ L 18/1	12.40, 12.51
Art 3	14.46, 14.50, 14.51, 14.56–14.62, 14.72, 14.75, 14.76, 14.108
Art 3(1)(b).....	14.62
Art 3(2)	14.64
Art 5	14.48, 14.51, 14.74
Art 7	14.51
Art 8	14.90
Art 8(2)	14.97
Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts ‘similar medicinal product’ and ‘clinical superiority’ [2000]	
OJ L 103/5	12.40
Art 3.3(b) and (c)	14.79
Art 3.3(d).....	14.94
Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and	

veterinary use and establishing a European Medicines Agency [2004] OJ L 136/1	1.43, 4.83, 4.115
Art 6	13.93
Art 14(11)	14.18, 14.100
Art 24	4.121
Art 26	4.121
Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 [2006] OJ L 378/1	12.47–12.52, 13.09, 14.98, 14.106
Art 7	12.48, 14.103
Art 8	12.48
Art 36	12.49, 14.99, 14.105, 14.108
Art 36(1) to (3)	14.101, 14.103
Art 36(4)	14.100, 14.103
Art 37	12.49, 14.99, 14.104, 14.108
Art 52	14.103
Art 104	8.33–8.35
Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 [2007] OJ L 324/121	3.34–3.41, 3.45, 3.135
Recital 14	3.133
Art 29	3.38
Regulation (EC) No 765/2008 of the European Parliament and of the Council of 9 July 2008 setting out the requirements for accreditation and market surveillance relating to the marketing of products and repealing Regulation (EEC) No 339/93 [2008] OJ L 218/30	7.82
Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the	

supplementary protection certificate for medicinal products [2009]		the Council with regard to principles and guidelines of good manufacturing practice for active substances for medicinal products for human use [2014] OJ L 337/1	3.49
OJ L 152/1	12.06, 13.81–13.82	Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the Council and Commission Regulation (EC) No 1852/2001 [2015] OJ L 327/1	9.145
Art 3	13.72	Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation) [2016] OJ L 119/1	2.138, 9.46, 9.50
Art 3(1)	13.76	Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC [2017] OJ L 117/1	1.99, 7.10, 7.19, 15.25–15.26
Art 3(3)	13.77	Art 117	7.71
Art 3(a)	13.81	Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU [2017] OJ L 117/176	7.10, 15.25–15.26
Art 3(c)	13.81	Regulation (EU) 2017/1001 of the European Parliament and of the Council of 14 June 2017 on the European Union trade mark [2017] OJ L 154/1	13.84
Art 3(d)	13.81	Art 4	13.84
Art 6	13.73	Commission Regulation (EU) 2018/781 of 29 May 2018 amending Regulation (EC) No 847/2000 as regards the definition of the concept ‘similar medicinal product’ [2018] OJ L 132/1	12.40, 14.81
Art 7	13.72	Regulation (EU) 2018/1725 of the European Parliament and of the Council of 23	
Art 13(2)	13.08		
Regulation (EU) No 1257/2012 of the European Parliament and of the Council of 17 December 2012 implementing enhanced cooperation in the area of the creation of unitary patent protection [2012] OJ L 361/1	13.14		
Council Regulation (EU) No 1260/2012 of 17 December 2012 implementing enhanced cooperation in the area of the creation of unitary patent protection with regard to the applicable translation arrangements [2012] OJ L 361/89	13.14		
Regulation (EU) No 1307/2013 of the European Parliament and of the Council of 17 December 2013 establishing rules for direct payments to farmers under support schemes within the framework of the common agricultural policy and repealing Council Regulation (EC) No 637/2008 and Council Regulation (EC) No 73/2009 [2013] OJ L 347/608	9.121		
Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC [2014] OJ L 158/1	2.26, 8.02–8.15, 8.39–8.58		
Art 28(2)	8.40		
Art 29	8.14		
Art 29(2)	8.41		
Art 31(c)	8.41		
Art 32(c)	8.41		
Art 35	8.42		
Arts 36 to 38	8.55		
Arts 41 and 42	2.95		
Art 104	8.15		
Annex I	8.46		
Annex III	2.95, 8.56		
Commission Delegated Regulation (EU) No 1252/2014 of 28 May 2014 supplementing Directive 2001/83/EC of the European Parliament and of			

October 2018 on the protection of natural persons with regard to the processing of personal data by the Union institutions, bodies, offices and agencies and on the free movement of such data, and repealing Regulation (EC) No 45/2001 and Decision No 1247/2002/EC [2018] OJ L 295/39	2.138
Regulation (EU) 2019/933 of the European Parliament and of the Council of 20 May 2019 amending Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products [2019] OJ L 153/1	13.78
Directives	
Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products [1965] OJ 22/369	1.25
Art 4.8(a)	11.56
Council Directive 85/374/EEC of 25 July 1985 on the approximation of the laws, regulations and administrative provisions of the Member States concerning liability for defective products [1985] OJ L 210/29	10.118, 10.129, 10.156, 10.159
Art 1	10.35, 10.36, 10.79
Art 3	10.34, 10.89
Art 3(2)	10.39, 10.87
Art 3(3)	10.19, 10.39, 10.86
Art 4	10.36
Art 6	10.35, 10.36, 10.40–10.57
Art 6(1)	10.49
Art 7	1.02, 10.02, 10.36
Art 7(a)	10.58–10.59
Art 7(b)	10.60
Art 7(c)	10.61
Art 7(d)	10.62–10.63
Art 7(e)	10.09, 10.16–10.90, 10.64–10.68
Art 7(f)	10.69
Art 8	10.36
Art 8(1)	10.81
Art 8(2)	10.70, 10.81
Art 9	10.36, 10.71
Art 11	10.36, 10.74
Art 12	10.36
Art 15	10.36
Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the	
prices of medicinal products for human use and their inclusion in the scope of national health insurance systems [1989] OJ L 40/8	
Art 7	11.30
Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of the Member States relating to active implantable medical devices [1990] OJ L 189/17	6.51, 7.09, 7.19
Council Directive 93/42/EEC of 14 June 1993 concerning medical devices [1993] OJ L 169/1	6.51, 7.09, 10.156
Art 11(13)	1.99
Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions [1998] OJ L 213/13	13.48
Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices [1998] OJ L 331/1	6.51, 7.09, 11.51
Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use [2001] OJ L 20/1	1.21, 1.30, 2.16, 8.01–8.02, 8.21, 8.26
Art 25	10.160
Commission Directive 2001/62/EC of 9 August 2001 amending Directive 90/128/EEC relating to plastic materials and articles intended to come into contact with foodstuffs [2001] OJ L 221/18	13.107
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [2001] OJ L 83/1	1.27, 1.32, 1.36, 1.43, 1.84, 2.02, 2.15, 2.30, 3.45, 11.52–11.59, 12.36–12.39, 14.05
Recital 10	12.38, 14.11
Art 1(20)	13.93
Art 2(1)	11.55
Art 2(2)	11.53
Art 3	12.44

Art 3(7)	14.62	Recital 8	3.134
Art 6	14.10, 14.30–14.32	Art 2(a)	3.134
Art 6(2)	14.26, 14.34	Art 2(c)	3.134
Art 8	12.36, 12.37, 14.10, 14.11	Directive 2004/27/EC [2004] OJ L 136/34	
Art 8(3)	12.44	amending Dir 2001/83/EC	4.83
Art 8(3)(i)	12.37, 14.15	Directive 2004/27/EC of the European	
Art 8(3)(ia)	4.115	Parliament and of the Council of 31	
Art 10(1)	11.56, 12.36, 12.39,	March 2004 amending Directive 2001/	
	12.49, 14.10, 14.13, 14.16,	83/EC on the Community code relating	
	14.18, 14.21, 14.100	to medicinal products for human use	
Art 10(1)(a)(iii)	11.56	[2004] OJ L 136/34	1.32, 1.43
Art 10(2)	11.56, 14.27	Directive 2004/28/EC of the European	
Art 10(2)(b)	14.21, 14.23, 14.24, 14.35	Parliament and of the Council of 31	
Art 10(3)	11.56, 12.36, 14.14, 14.25,	March 2004 amending Directive 2001/	
	14.27, 14.28, 14.37, 14.41	82/EC on the Community code relating	
Art 10(4)	12.36	to veterinary medicinal products [2004]	
Art 10(5)	14.28, 14.42–14.45	OJ L 136/58	4.83
Art 10a	12.36, 14.11	Council Directive 2004/74/EC of 29 April	
Art 10b	12.36, 12.37	2004 amending Directive 2003/96/EC	
Art 10c	12.36	as regards the possibility for certain	
Arts 32 to 34	4.120	Member States to apply, in respect	
Art 94	11.59	of energy products and electricity,	
Art 104	4.121	temporary exemptions or reductions in	
Annex I, Pt II, s 3	14.37	the levels of taxation [2004]	
Annex I, Pt IV, s 1	3.42	OJ L 157/87	1.36–1.37
Directive 2001/95/EC of the European		Commission Directive 2005/28/EC of 8	
Parliament and of the Council of 3		April 2005 laying down principles and	
December 2001 on general product		detailed guidelines for good clinical	
safety [2002] OJ L 11/4	7.03	practice as regards investigational	
Directive 2002/98/EC of the European		medicinal products for human	
Parliament and of the Council of 27		use, as well as the requirements for	
January 2003 setting standards of quality		authorisation of the manufacturing or	
and safety for the collection, testing,		importation of such products [2005]	
processing, storage and distribution of		OJ L 91/13	8.21, 8.23
human blood and blood components		Commission Directive 2006/17/EC	
and amending Directive 2001/83/EC		of 8 February 2006 implementing	
[2003] OJ L 33/30	3.126	Directive 2004/23/EC of the European	
Commission Directive 2003/94/EC of		Parliament and of the Council as regards	
8 October 2003 laying down the		certain technical requirements for the	
principles and guidelines of good		donation, procurement and testing of	
manufacturing practice in respect of		human tissues and cells [2006] OJ L	
medicinal products for human use and		330M/162	3.58
investigational medicinal products for		Commission Directive 2006/86/EC of	
human use [2003] OJ L 262/22	3.49,	24 October 2006 implementing	
	8.24–8.25	Directive 2004/23/EC of the European	
Directive 2004/23/EC of the European		Parliament and of the Council as	
Parliament and of the Council of 31		regards traceability requirements,	
March 2004 on setting standards of		notification of serious adverse	
quality and safety for the donation,		reactions and events and certain	
procurement, testing, processing,		technical requirements for the coding,	
preservation, storage and distribution		processing, preservation, storage and	
of human tissues and cells [2004]		distribution of human tissues and cells	
OJ L 102/48	3.58, 3.124, 3.133, 3.135	[2006] OJ L 294/32	3.58

Directive (EU) 2015/2436 of the European Parliament and of the Council of 16 December 2015 to approximate the laws of the Member States relating to trade marks [2015] OJ L 336/1	13.84, 13.100
Art 3	13.84
Art 4	13.89

INTERNATIONAL

Agreement on the European Economic Area 1994 (EEA Agreement)	
Art 11	11.59
Art 12	11.59
Art 13	11.59
Agreement on Trade-Related Aspects of Intellectual Property Rights 1994 (TRIPS)	
Art 33	13.08
Art 39(3)	12.34
Berne Convention for the protection of Literary and Artistic Works 1886	12.11
Convention on Psychotropic Substances 1971	9.159
Declaration of Helsinki 1964 (World Medical Association)	1.19, 8.15
European Convention on Human Rights 1950	11.17
Art 2	11.33–11.37, 11.39, 11.42–11.43
Art 3	11.38–11.41
Art 8	11.42–11.43
Art 8(1)	11.42
Art 8(2)	11.42
Art 34	11.20
Art 41	11.23
Protocol 1, Art 1	11.36
European Patent Convention 1973	13.12, 13.28–13.29
Art 52(1)	13.45
Art 54(4)	13.26
Art 54(5)	13.26
Art 69(1)	13.63
Protocol on the Interpretation of Article 69	13.66
Paris Convention for the Protection of Industrial Property 1883 (Paris Convention)	13.16
Patent Cooperation Treaty 1970	13.15
UN Single Convention on Narcotic Drugs 1961	9.159
United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances 1988	9.159

UNITED KINGDOM

Statutes

Apothecary, Wares Drugs and Stuffs Act 1450 s 2	1.03
Bail Act 1976	9.95
Bribery Act 2010 ss 1 to 7	9.44
s 7	9.30
Cancer Act 1939	1.11
Care Act 2014	3.128, 6.12, 8.38
s 73(2)	11.17
s 73(3)	11.17
s 110(7)	8.37
Civil Liability (Contribution) Act 1978 . .	11.24
s 1(1)	10.14
s 1(6)	10.14
s 2(1)	10.14
s 6	10.14
Civil Liability (Contribution) Act 1987 . .	10.81
s 1(3)	10.82
Company Directors Disqualification Act 1986 s 2	9.97
Congenital Disabilities (Civil Liability) Act 1976	10.169
Consumer Protection Act 1987	1.32, 7.75, 7.80, 9.49, 10.02, 10.19–10.90, 10.129, 10.159, 10.160
Pt I	10.19, 10.28, 10.32
Pt II	9.79
s 1	10.34
s 1(1)	10.19, 10.28
s 2(1)	10.35, 10.79
s 2(2)	10.34
s 2(2)(b)	10.39
s 2(3)	10.34, 10.36, 10.39, 10.86
s 3	10.35, 10.36
s 4(1)	10.36
s 4(1)(e)	10.09
s 4(2)	10.74
s 5	10.77
s 5(1)	10.36, 10.71
s 5(2)	10.71
s 5(3)	10.36
s 5(5) to (7)	10.77
s 6(1)	10.76
s 6(4)	10.36
s 7	10.36, 10.55
s 12	9.55
ss 13 to 18	9.79
Sch 2	9.79
Consumer Rights Act 2015	7.75, 7.79

s 37	9.79	Human Fertilisation and Embryology	
Sch 5	9.79	Act 1990	3.119
Copyright, Designs and Patents Act 1988		Human Fertilisation and Embryology	
s 3	12.23	Act 2008	3.114, 3.119
s 12	12.06, 12.25	Human Rights Act 1998 6.12, 11.02, 11.17–11.25	
s 12(3)	12.06	Pt 20	11.24
s 12(7)	12.06	s 2	11.25
s 107	9.32	s 3	11.25
s 159	12.11	s 6(1)	11.18, 11.19, 11.23, 11.25
s 216	12.06	s 6(3)	11.18
Corporate Manslaughter and Corporate		s 6(3)(b)	11.17
Homicide Act 2007	9.42–9.43	s 6(6)	11.18
s 1	9.42	s 7	11.15
s 8	9.42	s 7(1)	11.19
s 19	9.42	s 7(1)(a)	11.22
s 20	9.42	s 7(5)	11.21
Crime and Courts Act 2013		s 7(7)	11.20
s 45	9.92	s 8(1)	11.23
Sch 17	9.92	s 8(2)	11.23
Criminal Attempts Act 1981		s 8(5)(b)	11.24
s 1(1)	9.17	s 22(4)	11.22
Criminal Finances Act 2017		Human Tissue Act 2004	3.123, 10.170
Pt 3	9.30	Human Tissue (Scotland) Act 2006	3.123
Criminal Justice and Public Order Act 1994		Intellectual Property Act 2014	
s 34	9.83	s 22	12.11
Criminal Law Act 1977		Law Reform (Contributory Negligence) Act	
s 1	9.17	1945	10.81
Criminal Procedure and Investigations		s 1	10.11
Act 1996	9.95	Law Reform (Miscellaneous Provisions) Act	
Crown Proceedings Act 1947		1934	10.13, 10.76
s 40	11.14	Law Reform (Miscellaneous Provisions)	
Customs and Excise Management Act 1979		Act 1945	
s 139	9.144	s 1(1)	10.11
s 170(1)	9.108	Legislative and Regulatory Reform	
s 170(2)	9.114 t9.8	Act 2006	7.82
Sch 3	9.144	Limitation Act 1980	
Data Protection Act 2018	9.46	s 10	10.14
Enterprise Act 2002 (EA)	7.76	s 11	10.12
s 188	9.32	s 11A	10.77
Equality Act 2010	6.12, 6.17	s 11A(3)	10.74
European Communities Act 1972	9.47	s 11A(4)	10.74
European Union (Withdrawal)		s 11A(4)(b)	10.77
Act 2018	8.05, 9.50	s 11A(5)	10.76
European Union (Withdrawal Agreement)		s 12	10.13
Act 2020	9.50	s 14	10.12, 10.159
Extradition Act 2003	9.85	s 14(1A)	10.80
Fatal Accidents Act 1976	10.13, 10.76	s 28	10.12, 10.74
s 5	10.11	s 33	10.12, 10.74, 10.159
Food Safety Act 1990		s 329(2A)	10.74
s 1	10.130 t10.1	Medicines Act 1968	1.11, 1.22,
Fraud Act 2006		1.25, 2.14, 4.59, 9.11, 9.47,	
ss 1 to 4	9.41	9.51–9.54, 10.130	
Health and Social Care Act 2012	6.12, 6.15	Pt III	9.51, 9.52
Hearing Aid Council Act 1986	11.51	Pt IV	9.54

s 2	10.130 t10.1	s 18(2)	9.121, 9.160
s 6	1.26, 10.130 t10.1	s 20	9.90
s 58	9.51, 9.52	s 21	9.31
s 62	9.51, 9.52	s 23(1)	9.25
s 63	9.52	s 23(4)(a)	9.25
s 64	9.52	s 23(4)(b)	9.25
s 67	9.52	s 23(4)(c)	9.25
s 67(1B)	9.53	s 25	9.20
s 72A	9.54	s 28	9.117, 9.119
s 77	9.54	s 37(1)	9.106–9.107, 9.109, 9.111
s 78	9.54	Sch 2	9.19, 9.108, 9.109
s 79(2)	9.54, 9.92	Sch 2, Pt I, para 3	9.110
s 84(1)	9.54	Sch 4	9.20, 9.24, 9.25, 9.27
s 84(2)	9.54	National Health Service Act 1977	10.04, 10.125, 10.130, 10.130 t10.1, 11.29
s 84(A1)	9.54	s 1(1)	11.27
s 133(2)	10.04, 10.10	s 3(1)	11.27
Ministry of Health Act 1919		Patents Act 1977	13.09
s 2	10.04, 10.130	s 1(1)	13.18
Misuse of Drugs Act 1971	9.39, 11.51	s 1(2)	13.47
Pt II	9.108, 9.109, 9.110	s 1(c)	13.45
Pt IV	9.109	s 2(1) to (3)	13.20
s 2(1)	9.19–9.27	s 2(2)	13.31
s 2A	9.19	s 2(3)	13.31
ss 3 to 6	9.19	s 3	13.31, 13.50
s 3	9.114 t9.8	s 4A	13.50
s 3(1)	9.142, 9.157	s 4A(3) and (4)	13.26
s 3(2)(b)	9.157	s 5(1)	13.19
s 4(1)	9.120, 9.128, 9.142, 9.147, 9.148	s 5(2) and (2A)	13.19
s 4(2)(a) and (b)	9.114 t9.8	s 14	13.56
s 4(3)	9.114 t9.8	s 14(3)	13.39
s 4(5)	9.142	s 15(10)(c)	13.56
s 5(1)	9.120, 9.142, 9.147, 9.148	s 17	13.56
s 5(2)	9.114 t9.8	s 18	13.57
s 5(3)	9.114 t9.8	s 21(1)	13.57
s 6	9.114 t9.8, 9.119, 9.148	s 24	13.58
s 6(1)	9.120, 9.147	s 25	12.06, 13.08, 13.59
s 6(2)	9.117, 9.118, 9.119	s 25(3)	13.59
s 7	9.19	s 25(4)	13.59, 13.60
s 7(1)(b)	9.117, 9.120, 9.147	s 28	13.59
s 7(3)	9.128	s 60	13.61
s 7(4)	9.128	Sch A2(3)	13.48
s 7(4)(a)	9.121, 9.149	Police and Criminal Evidence Act 1984	
s 7A	9.19	Pt II	9.77
s 8	9.114 t9.8	Pts III to VI	9.83
s 8(d)	9.135	s 11	9.78
s 9A	9.23, 9.114 t9.8	ss 47 to 47ZM	9.84
s 11	9.24	Sch 1	9.77
s 11(2)	9.24	Powers of Criminal Courts (Sentencing) Act 2000	
ss 12 and 13	9.24	s 110(7)	9.118
s 12(6)	9.24	Proceeds of Crime Act 2002	9.02–9.03, 9.35–9.37, 9.40, 9.81, 9.82,
s 13(3)	9.24		
s 17	9.25		
s 18	9.25		
s 18(1)	9.27		

9.86, 9.87, 9.92, 9.94, 9.98, 9.112, 9.116, 9.118	r 48.6A 10.03
Pts 2 to 4 9.86	r 54.1(2)(a). 11.03
Pt 5 9.86	r 54.1(2)(f). 11.07
Pt 7 9.86	r 54.12(3). 11.04
Pt 8 9.86	r 54.19. 11.14
ss 327 to 329. 9.35	r 54.2. 11.14
s 327(2A). 9.39	r 54.3. 11.14
s 328(3). 9.39	r 54.3(2). 11.14
s 329(2A). 9.39	r 54.4. 11.04
s 330 9.37	r 54.5(1). 11.05
s 340 9.35	General Product Safety Regulations 2005 (SI 2005/1803) 7.03, 7.13, 7.74, 7.75, 7.80, 9.49, 9.55
s 340(2)(b). 9.39	Good Laboratory Practice Regulations 1999 (SI 1999/3106)
Prosecution of Offences Act 1985	reg 12 9.48
s 6(1) and (2). 9.94	reg 15 9.48
Psychoactive Substances Act 2016	Human Medicines Regulations 2012, SI 2012/ 1916. 9.35, 9.39
s 3 9.114	Pt 14 9.45
ss 4 to 9. 9.113	Human Medicines Regulations 2012 (SI 2012/1916) 1.27, 9.49, 9.56–9.73, 9.126
Sch 1 9.114	Human Medicines Regulations 2012, SI 2012/1916
Public Bodies (Admission to Meetings) Act 1960. 6.12, 6.41	Ch 3 3.106
Registered Designs Act 1949	Human Medicines Regulations 2012 (SI 2012/1916)
s 8 12.06	Pt 3 9.57, 9.58 ¶9.1–¶9.3
Sale of Goods Act 1979	Pt 4 9.57, 9.58 ¶9.5
s 14 10.04	Pt 5 9.61
Senior Courts Act 1981	Pt 6 9.64
s 30 11.14	Pt 7 9.64
s 31(2). 11.14	Pt 9 9.64
s 31(3). 11.07	Pt 10 9.63
s 31(4). 11.15	Pt 11 9.65
s 51(1). 11.16	Pt 12 9.57, 9.58 ¶9.4
Serious Crime Act 2007	Pt 12A. 9.66, 9.69 ¶9.6
ss 44 to 46. 9.17	Pt 13 9.67, 9.69, 9.70, 9.72 ¶9.7
s 52 9.17	Pt 14, Ch 2 9.67, 9.71
Sch 4, para 1. 9.18	Pt 16 9.73
Therapeutic Substances Act 1925 1.10, 4.57	Human Medicines Regulations 2012 (SI 2012/1916)
Trade Marks Act 1994	reg 10 1.29
s 42 12.06	reg 13 9.135
s 92 9.32	reg 16A(1)(a). 9.132
Vaccine Damage Act 1979	reg 16A(1)(b) 9.133
s 7 10.168	reg 16A(1)(c). 9.134
Vaccine Damage Payments Act 1979 . . . 10.168	reg 16A(3) 9.135
Venereal Diseases Act 1917 1.11	reg 43(2). 9.60
	regs 49 to 67. 9.61
	regs 68 to 72. 9.61
	regs 73 to 78B 9.61
Statutory Instruments	
Blood Safety and Quality Regulations 2005 (SI 2005/50). 10.170	
Civil Procedure Rules 1998 (SI 1998/3132) (L. 17)	
Pt 7 11.19	
Pt 54 11.03	
Pt 54A PD 11.04	
r 19.10 to 19.15 10.03	

regs 79 to 94.....	9.62	Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018 (SI 2018/1055).....	9.104, 9.125, 9.129
regs 95 to 101.....	9.62	reg 3.....	9.126
regs 119 to 121.....	9.64	reg 4.....	9.131
regs 150 to 152.....	9.64	regs 6 and 7.....	9.127
reg 161.....	3.104	Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015 (SI 2015/704).....	9.108, 9.125, 9.128
reg 166.....	9.64	Misuse of Drugs (Licence Fees) Regulations 2010 (SI 2010/2497).....	9.121, 9.125, 9.140, 9.154
reg 167.....	9.132, 9.146	Misuse of Drugs Regulations 2001 (SI 2001/3998).....	9.125, 9.134
reg 170(3).....	9.63	reg 2.....	9.109
regs 175 and 176.....	9.63	reg 2(1).....	9.126, 9.141–9.142
reg 175(3).....	9.63	regs 4 to 27.....	9.27
reg 175(3)(c).....	9.63	reg 4.....	9.109
reg 176(1).....	9.63	reg 5.....	9.148, 9.149
reg 207.....	9.65	reg 12.....	9.148, 9.149
reg 209.....	9.65	reg 16A.....	9.131
reg 210(5) and (6).....	9.65	reg 25.....	9.109
reg 210A(3) and (4).....	9.65	Sch 6.....	9.27
reg 211.....	9.65	Schs 1 to 5.....	9.149
reg 308.....	9.71	Sch 1.....	9.104, 9.108, 9.121, 9.124, 9.127, 9.149
reg 334.....	9.73	Sch 2.....	9.104, 9.127, 9.130, 9.146, 9.149
reg 335.....	9.68, 9.70, 9.71	Sch 4.....	9.129, 9.142
reg 336.....	9.70	Sch 5.....	9.142, 9.149
regs 208 and 209.....	9.65	Misuse of Drugs (Safe Custody) Regulations 1973 (SI 1973/798).....	9.153
regs 279 to 303.....	9.71	National Institute for Health and Care Excellence (Constitution and Functions) Regulations 2013 (SI 2013/259).....	6.13, 6.19
regs 336 and 337.....	9.69	reg 7.....	6.11
Human Tissue (Quality and Safety for Human Application) Regulations 2007 (SI 2007/1523).....	3.123	Patent Rules 2007 (SI 2007/3291).....	13.11
Medical Devices Regulations 2002 (SI 2002/618).....	1.89, 7.13, 7.80, 9.49, 9.55, 15.20	r 26.....	13.56
reg 12.....	9.120	r 33.....	13.57
Medicines (Advisory Bodies) Regulations 2005 (SI 2005/1094).....	10.130 ¶10.1	r 37.....	13.59
Medicines (Committee on Safety of Medicines) Order 1970 (SI 1970/1257).....	10.130 ¶10.1	r 40.....	13.59
Medicines for Human Use (Clinical Trials) (Amendment No. 2) Regulations 2006 (SI 2006/2984).....	8.22	r 41.....	13.59
Medicines for Human Use Clinical Trials Amendment Regulations 2006 (SI 2006/1928).....	8.21, 8.23	r 96.....	13.57
Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031).....	8.01, 8.13, 8.15, 8.21, 8.24, 8.26, 8.28, 8.38	Proceeds of Crime Act 2002 (Exceptions to Overseas Conduct Defence) Order 2006 (SI 2006/1070).....	9.39
Medicines for Human Use (Marketing Authorisations Etc.) Regulations 1994 (SI 1994/3144).....	10.130 ¶10.1	Supplementary Certificates (Amendment) (EU Exit) Regulations 2020 (SI 2020/1471).....	13.83
Misuse of Drugs Act 1971 (Amendment) Order 2019 (SI 2019/1323).....	9.110–9.113	Vaccine Damage Payments Act 1979 Statutory Sum Order 2007 SI 2007/1931).....	10.168
Misuse of Drugs (Amendment No 2) (England, Wales and Scotland) Regulations 2013 (SI 2013/625).....	9.129		

UNITED STATES

Federal Food, Drug, and Cosmetic Act 1938.	1.23, 2.13, 4.51	Kefauver Harris Amendment 1962.	1.24
Federal Pure Food and Drug Act 1906 (Wiley Act)	1.22	Orphan Drug Act 1983	4.55
Federal Tech Transfer Act 1986.	4.55	Prescriptions Drug User Fee Act 1992 (PDUFA)	4.67
		Public Readiness and Emergency Preparedness Act 2005 (PREP).	1.83

List of Abbreviations

AAVA	adeno-associated virus
ABPI	Association of the British Pharmaceutical Industry
ACD	Appraisal Consultation Document
ACMD	Advisory Council on the Misuse of Drugs
ADE	adverse drug event
ADHD	attention deficient deficit hyperactivity disorder
ADR	adverse drug reaction
AI	artificial intelligence
AIFA	Italian Medicines Agency
AIMD	Directive 90/385/EEC regarding active implantable medical devices
ALS	amyotrophic lateral sclerosis
ARBS	angiotensin receptor blockers
ARMD	adverse reaction to metal wear debris
ATMP	advanced therapy medicinal products
ATPS	adenosine triphosphate
CAR-T	Chimeric Antigen Receptor T cells
CBD	cannabidiol
CBPMs	cannabis-based products for medicinal use in humans
C-CASA	Columbia-Classification Algorithm for Suicide Assessment
CDs	controlled drugs
CGRP	calcitonin gene related peptide
CHM	Commission on Human Medicines
CHMP	Committee for Medicinal Products for Human Use/Committee for Human and Medicinal Products
CHO	Chinese hamster ovary
CI	confidence interval
CIOMS	Council for International Organizations of Medical Sciences
CJEU	Court of Justice of the European Union
CMA	Competition and Markets Authority
CMDh	Co-ordination Group for Mutual Recognition and Decentralised Procedures
CML	chronic myeloid leukaemia
CMO	Chief Medical Officer for England
CMS	Concerned Member States
COMP	Committee for Orphan Medicinal Products
COPD	chronic obstructive pulmonary disease
CPA	Consumer Protection Act 1987
CPAP	continuous positive airway pressure
CPR	Civil Procedure Rules
CPRD	Clinical Practice Research Datalink

xxxviii LIST OF ABBREVIATIONS

CPS	Crown Prosecution Service
CRA	Consumer Rights Act 2015
CRISPR	clustered regularly interspaced short palindromic repeats
CSD	Committee on Safety of Drugs
CSM	Committee on the Safety of Medicines
C-SSRS	Columbia-Suicide Severity Rating Scale
CTA	Clinical Trial Authorisation
CTIS	Clinical Trials Information System
CTR	Clinical Trials Regulations
CTS	common technical specifications
DBS	Disclosure and Barring Service
DEA	Devices Expert Advisory Committee
DFLU	Drugs and Firearms Licensing Unit
DH	dexmedetomidine hydrochloride
DHSC	Department of Health and Social Care
DMF	dimethylfumarate
DPA	Deferred Prosecution Agreement
DPP	Director of Public Prosecutions
DSUR	Development Safety Update Report
EA	Enterprise Act 2002
EAG	Expert Advisory Group
ECDD	Expert Committee on Drug Dependence
ECHR	European Convention on Human Rights
ECJ	European Court of Justice
ECtHR	European Court of Human Rights
EEA	European Economic Area
EMA	European Medicines Agency
EMA	European Medicines Evaluation Agency
ENCePP	European Network of Centres for Pharmacoepidemiology and Pharmacovigilance
EP	European Patent
EPC 2000	European Patent Convention 2000
EPO	European Patent Office
EPO	erythropoietin
ERG	Evidence Research Group
ERG	Evidence Review Group
EU IVDR	Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU
EUMDR	Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC
EUTM	European Union Trade mark
FAD	Final Appraisal Document
FDA	Food and Drug Administration (USA)
FEV	forced expiratory volume
FSA	Food Standards Agency

GBH	grievous bodily harm
GcMAF	Globulin component Macrophage Activating Factor
GCP	glucosamine-containing product
GCP	good clinical practice
GDPR	General Data Protection Regulation
GLO	group litigation order
GMA	global marketing authorisation
GMC	General Medical Council
GMP	good manufacturing practice
GPDR	General Practice Research Database
GPSR	General Product Safety Regulations 2005
GSK	GlaxoSmithKline
HBV	hepatitis B virus
HCV	hepatitis C virus
HIV	human immunodeficiency virus
HMRs	Human Medicines Regulations 2012
HRA	Human Rights Act 1998
HRT	hormone replacement therapy
HST	Highly Specialised Technology
HTA	Health Technology Assessment
ICER	incremental cost-effectiveness ratio
ICH	International Conference on Harmonisation
ICO	Information Commissioner's Office
ICRS	individual case safety reports
Ig	immunoglobulin
IMI	Innovative Medicines Initiative
IMP	investigational medicinal products
INN	international non-proprietary name
IP	intellectual property
IPO	Intellectual Property Office
ISSCR	International Society for Stem Cell Research
IVD	in vitro diagnostic devices
IVDD	Directive 98/79/EC regarding in vitro diagnostic medical devices
IVF	<i>in vitro</i> fertilisation
LA	licensing authority
LEA	law enforcement agency
LPP	legal professional privilege
MA	marketing authorisation
MA(IMP)	manufacturer's authorisation for investigational medicinal products
MAOIs	mono-amine oxidase inhibitors
MDA	Misuse of Drugs Act 1971
MDD	Directive 93/42/EEC regarding medical devices
MDEG	Medical Devices Expert Group
MDRS	Misuse of Drugs Regulations 2001
MedRA	Medical Dictionary for Regulatory Activities
MEF	monoethyl fumurate esters
MHRA	Medicines and Healthcare products Regulatory Agency
MLA	Mutual Legal Assistance

xl LIST OF ABBREVIATIONS

MoM	Metal on Metal
mRNA	messenger RNA
MS	multiple sclerosis
NAS	new active substances
NCA	National Crime Agency
NDS	National Drugs Control System
NIBSC	National Institute for Biological Standards and Control
NICE	National Institute for Health and Care Excellence
NIH	National Institutes of Health
NIHR	National Institute for Health Research
NRG	Name Review Group
OTC	over-the-counter
PACE	Police and Criminal Evidence Act 1984
PAGB	Pharmaceutical Association of Great Britain
PCR	polymerase chain reaction
PCT	Patent Cooperation Treaty
PDCO	Paediatric Committee
PDUFA	Prescriptions Drug User Fee Act
PhVWP	Pharmacovigilance Working Party
PIL	patient information leaflet
PIP	Paediatric Investigation Plan
PMCPA	Prescription Medicines Code of Practice Authority
PMDA	Pharmaceutical and Medical Devices Agency (Japan)
PML	progressive multifocal leukodystrophy
POA	Prosecution of Offences Act
POCA	Proceeds of Crime Act 2002
POM	prescription-only medicines
PPE	Personal Protective Equipment
PREP	Public Readiness and Emergency Preparedness
PSA	Psychoactive Substances Act 2016
PSMFs	pharmacovigilance system master files
PSURS	Periodic Safety Update Reports
PUMA	paediatric use marketing authorisation
QALY	quality adjusted life year
QPPV	qualified person responsible for pharmacovigilance
RCT	randomised controlled trials
RMP	Risk Management Plan
RMS	reporting Member State
RNA	ribonucleic acid
RUI	released under investigation
SARs	Suspicious Activity Reports
SFO	Serious Fraud Office
SLS-COPD	Salford Lung Study in chronic obstructive pulmonary disease
SMEs	small and medium-sized enterprises
SPARCL	Stroke Prevention by Aggressive Reduction in Cholesterol Levels
SPC	Summary of Product Characteristics
SPC	supplementary protection certificate
SSP	Serious Shortage Protocol

SUSARs	serious unexpected suspected adverse reactions
SWAN	syndromes without a name
TALeNs	transcription activator-like effector nucleases
TFEU	Treaty on the Functioning of the European Union
THC	tetrahydrocannabinol
TM	trade mark
TNF	tumour necrosis factor
TRIPS	(Agreement on) Trade-Related Aspects of Intellectual Property Rights
UKCA	UK Conformity Assessed
UKIPO	UK Intellectual Property Office
UK MDR	the Medical Devices Regulations 2002 (SI 2002/618, as amended)
UKPDS	UK Prospective Diabetes Study
UMC	Uppsala Monitoring Centre
VERICC	Values, Ethics and Rationing in Critical Care Task Force
VIE	vacuum insulated evaporator
WAMD	wet age-related macular degeneration
WHO	World Health Organization
WIPO	World Intellectual Property Organization

Index

Active Implantable Medical Devices

Directive 6.51–6.52, 7.09, 7.19

adenine 5.58, 5.60

adenosine deaminase deficiency 3.76, 3.78

ADHD drugs 4.38, 4.39

advanced therapy medicinal products

(ATMPs) 3.32–3.61

anonymised traceability 3.58

ATMP Regulation 3.34–3.40, 3.103

certification 3.44

challenges 3.58–3.61

classification 3.44, 3.52–3.57

combination ATMPs 3.33

Committee for Advanced Therapies

(EMA) 3.41–3.45

definition 3.33

doctors, exemptions for 3.106

donor selection criteria 3.58

gene therapy 1.71, 3.33, 3.38, 3.46, 3.54, 3.60

high costs 3.103

hospital exemption 3.103–3.105

inspection and licensing of establishments 3.58

manufacture 3.46–3.51, 3.104

marketing authorisation 3.36, 3.39, 3.42–

3.44, 3.103–3.105

Medicines and Healthcare products

Regulatory Agency (MHRA) 1.74, 3.52,

3.104–3.105, 3.131

potency, measure of 3.60

quality 3.41, 3.58, 3.61

quantity 3.58

recombinant cells 3.46–3.47

regulation 1.71–1.74, 3.34, 3.132, 3.133–3.135

risk-based approach 3.37, 3.42

small quantities, manufacture in 3.59

somatic cell therapy 1.71, 3.33, 3.38, 3.55

stem cells 1.71, 3.107

tissue engineering 1.71, 1.72–1.73, 3.33–3.34,
3.38, 3.57

unlicensed ATMPs 3.103–3.106

adverse events

adverse drug reactions (ADRs) 4.28–4.35

algorithms 2.90–2.91

background data, camouflage by 4.96, 4.166

benefits, assessment of 4.36–4.44

case reports 4.100, 4.102–4.112

cause and effect 2.91–2.92

clinical trials 2.87–2.102, 4.85, 4.163

Common Terminology Criteria for Adverse

Events system 2.93

deaths 2.88, 2.93–2.94, 2.104, 4.165

definition 2.86

expected events 2.80, 2.87–2.89

Independent Medicines and Medical Devices

Safety Review 2020 15.47

Medical Dictionary for Regulatory Activities

(MedDRA) 2.97–2.102

monoclonal antibodies 5.29, 5.34

pharmaco-epidemiology 1.31

pharmacovigilance 4.20, 4.21–4.44, 4.100–

4.112, 4.163–4.166

background data, camouflage by 4.96, 4.166

case reports 4.100, 4.102–4.112

clinical trials 4.85, 4.163

smoking 4.28–4.35, 4.172

Thalidomide 4.165, 4.170

Vioxx 4.05–4.06, 4.69, 4.89, 4.110,

4.130, 4.169

presentation of safety data 2.104

recording 2.97–2.102

reporting 1.33–1.35, 2.85, 2.87, 4.121, 4.126

safety 2.86–2.96

serious, classification as 2.88, 2.95, 2.104

signal, becoming a 4.20, 4.21–4.24

smoking 4.28–4.35, 4.172

statistically significant effects 4.41

stem cell tourism 3.108

Thalidomide 4.165, 4.170, 5.90, 10.17

treatment emergent adverse events 2.86

under-reporting 2.85

Vioxx 4.05–4.06, 4.69, 4.89, 4.110, 4.130, 4.169

Yellow Card scheme 1.33–1.34, 1.53, 4.46, 4.105

adverse reactions

adverse drug events 4.28–4.35

biosimilar medicinal products 3.21, 3.25

Independent Medicines and Medical Devices

Safety Review 2020 15.35

negligence 10.09

pharmacovigilance 4.01, 4.05–4.15, 4.26–

4.46, 4.87–4.88, 4.160

reporting 1.50–1.53, 4.113

risk-benefit balance 1.17–1.18

- advertising 4.113, 4.163, 9.67–9.72, 13.57
- aiding, abetting, counselling and procuring 9.17
- AIDS/HIV
 - CRISPR 3.73–3.74
 - dronabinol 9.130
 - funding for research 4.55
 - HIV Haemophiliacs Litigation 10.155
 - Infected Blood Inquiry 15.51–15.72
 - lopinavir/ritonavir 1.85, 1.101, 15.28
 - scurvy and Vitamin C 5.66
- Alofisel 3.98–3.99
- alternative medicines
 - herbal medicines 1.75–1.77, 4.105, 9.64, 11.34
 - homeopathic treatments 11.51
 - scientific testing 1.77
- amino acids 5.10–5.16, 5.20, 5.60, 5.65–5.67
- Aminorex 4.86
- amlodipine 4.43
- anaesthetics 4.10
- angiotensin receptor blockers (ARBs) 4.43
- animals
 - bovine spongiform encephalopathy 3.07
 - genetic identity, modifying the 13.49
 - hybridoma 5.04, 5.31
 - patents 13.49–13.50
 - serum 5.06, 5.28–5.29
 - studies 2.19–2.20
 - teratogenicity testing in animals 1.17
 - Vacanti mouse 3.100
- antibiotics 3.75, 5.93
- antibodies 1.89, 1.93, 3.15, 5.22–5.27, 15.32
 - see also* monoclonal antibodies
- appetite suppressants 4.86–4.88
- aprotinin 4.155, 4.158
- asbestos
 - causation 10.106, 10.111–10.116
 - Fairchild* 10.106, 10.112–10.116
 - mesothelioma 10.106
 - multiple employers 10.112–10.114
- aspirin 4.97, 10.149–10.151
- assisting or encouraging 9.17–9.18
- asthma deaths 4.98
- atenolol 4.138
- ATMPs *see* advanced therapy medicinal products (ATMPs)
- attempts 9.17
- attention deficit hyperactivity disorder (ADHD) 4.38, 4.39
- autologous transplants 3.134–3.136
- Avandia 4.144–4.152
- Avastin 11.51
- B lymphocytes 5.25–5.26, 5.31, 5.48
- balance of probabilities 10.99, 10.102, 10.108, 10.112–10.113
- benoxaprofen (Opren) 1.35, 4.131, 10.154
- beta agonists 4.98
- beta blockers 4.39, 4.60, 4.138, 12.20
- big data 2.132–2.150
 - biological products 5.103–5.106
 - Covid-19 5.104
 - definition 5.104
 - efficacy 2.143
 - ethical issues 2.136
 - European Medicines Agency (EMA) 2.137–2.139
 - human genome 5.103
 - human proteome 5.103
 - Medicines and Healthcare products Regulatory Agency (MHRA) 2.140–2.143
 - rare diseases 2.144–2.150
 - RNA 5.105
 - storage of data 2.134–2.135
- bioavailability 14.21, 14.26
- bioequivalence 14.21–14.23, 14.26, 14.31
- biological products 5.01–5.106
 - advanced therapy medicinal products (ATMPs) 3.01
 - big data 5.103–5.106
 - bovine spongiform encephalopathy 3.07
 - clinical hazards 5.98–5.102
 - definition 3.01, 5.01–5.07
 - DNA 5.04, 5.07, 5.53–5.77
 - features of biological products 3.09–3.11
 - legal framework 3.01–3.12
 - living cells 5.04–5.06
 - manufacture 3.12, 5.01
 - monoclonal antibodies 5.04, 5.08
 - non-enzyme, non-antibody biological therapies 5.37–5.52
 - nucleic acids 5.07
 - production 5.04–5.06
 - products made using biotechnology 3.03–3.07
 - products made without biotechnology 3.08
 - proteins (alias polypeptides) 5.07, 5.09–5.36
 - recombinant cells 3.03–3.07, 3.10
 - regulation 3.01–3.12
 - RNA 5.78–5.87
 - small molecule drugs 5.03, 5.98–5.102
 - testing for drug genotoxicity and carcinogenicity 5.88–5.97
 - types of biological drugs 5.07–5.08

biosimilar medicinal products 3.13–3.31

- active substance names 3.24, 3.25
- batch numbers 3.25
- challenges 3.27
- comparability studies 3.19, 3.22, 3.27
- data required 3.19–3.26
- definition 3.16
- indication, having more than one 3.20
- regulatory exclusivities 12.42
- replacement of products 3.28–3.31
- substitution 3.28–3.29
- switching 3.28–3.29, 3.31
- traceability of product and batch 3.23
- tradenames or brand names 3.24, 3.29
- variability 3.14, 3.18

Biotech Directive 13.48–13.49

blood and blood products *see also* **blood sugar**;

Infected Blood Inquiry

- blood pressure 4.136, 4.138–4.139, 4.172
- civil law, liability in 10.170
- cytokines 5.37–5.39
- European Union 3.126–3.127
- haemoglobin 5.16
- hepatitis B 11.34, 13.43, 15.51
- hepatitis C 5.38, 10.20, 10.45, 10.49, 15.51–15.72
- Medicines and Healthcare products Regulatory Agency (MHRA) 3.126–3.127
- myeloma 1.21, 5.07
- regulators, interplay of 3.132
- transfusions 5.06, 15.52

blood sugar 4.136, 4.144–4.152

- cardiovascular disease 4.145, 4.147–4.152
- clinical trials 4.146, 4.148–4.150
- diabetes 4.144–4.152
- heart attacks 4.149–4.150
- metformin 4.145, 4.147, 4.149
- pharmacovigilance 4.136, 4.144–4.152
- RECORD trial 4.148, 4.150–4.151
- regulation 4.144–4.152
- rosiglitazone (Avandia) 4.144–4.152
- statistics 4.147, 4.151
- surrogate markers 4.136, 4.146

bone marrow 5.45, 5.48, 5.90–5.91

borderline products 7.24–7.28

bovine spongiform encephalopathy (BSE) 3.07

brands

- biosimilar products 3.24, 3.29
- costs 6.21–6.22
- own brands 10.34, 10.89
- passing off 13.110, 13.114
- trade marks 12.17–12.18, 12.20–12.21, 13.87, 13.119
- Voluntary Scheme for Branded Medicines Pricing and Access 6.21–6.22

breach of statutory duty 10.04, 10.130–10.131

breast cancer 4.99, 5.08, 5.35, 5.96, 11.31

Brexit 15.02–15.26

- CE markings 7.38–7.39
- clinical trials 8.04–8.10, 8.58, 15.15–15.18
- criminal law, liability in 9.50
- divergence 7.06–7.07
- European Medicines Agency (EMA) 8.04
- medical devices 7.04–7.07, 7.15, 7.84, 15.19–15.26
- CE markings 7.38–7.39
- divergence 7.06–7.07
- Notified Bodies 7.56–7.59
- transition period 7.05–7.06, 7.14, 7.38
- vigilance requirements 7.45
- medicinal products 15.04–15.14
- Medicines and Healthcare products Regulatory Agency (MHRA) 10.128, 15.03, 15.07
- NICE and Health Technology Assessment (HTA) 6.24, 6.51
- Northern Ireland 13.83, 14.01, 15.05, 15.13–15.14, 15.26
- Notified Bodies 7.56–7.59
- pharmacovigilance system master files (PSMFs) 4.117
- regulation 1.80, 10.128, 14.01, 15.03
- trade marks 13.85
- transition period 7.05–7.06, 7.14, 7.38
- vigilance requirements 7.45

bribery 9.44–9.45

British Pharmacopoeia 3.02, 15.11

calcium channel blockers 4.43

cancer

- breast cancer 4.99, 5.08, 5.35, 5.96, 11.31
- Cancer Drugs Fund 6.43–6.44
- carcinogenicity, testing for 5.88–5.97
- causation 10.104, 10.109
- chemotherapy 5.48, 5.86, 5.91, 5.96, 9.124, 9.130, 11.28
- Chimeric Antigen Receptor T cells (CAR-T) 5.49–5.52
- epidemiology 10.104
- fast cell turnover 5.90
- gambling 4.71
- Herceptin therapy 5.08, 5.35, 11.31
- leukaemia 3.78, 5.48, 11.28
- lung cancer 4.12–4.13, 4.25, 4.29–4.31, 10.104, 10.109, 10.115
- lymphocyte therapies 5.49–5.52
- myeloma 1.21, 5.07
- orphan market exclusivity 14.55
- renal cancer 4.105
- smoking 4.12–4.13, 4.29–4.31, 10.104, 10.109

cannabis *see* **medicinal cannabis**

capacity 2.88, 8.13, 8.22, 8.41

carbergoline 4.88

cardiovascular disease/heart disease *see also*
heart attacks

blood sugar 4.145, 4.147–4.152

cholesterol 4.136, 4.140–4.143

oral contraception, risk of cardiovascular
injury from 10.51

pharmacovigilance 4.06, 4.32, 4.86, 4.89,
4.92, 4.96, 4.99

statins 4.09–4.10, 4.12, 4.16, 4.32, 4.44

weight loss drugs and valvular heart
disease 4.86–4.88

cartilage 5.45

causation

acceptable/unacceptable risk of
damage 10.98

adverse events 2.91–2.92

asbestos 10.111–10.116

balance of probabilities 10.99, 10.102, 10.108,
10.112–10.113

Bradford Hill criteria 4.19, 10.101, 10.108

but for test 10.111

civil law, liability in 10.94–10.122

contribution 10.81, 10.91

correlation 4.25

courts, approach of the 10.99–10.122

criminal law, liability in 9.14–9.16

doubling of risk principle 10.107–10.108

epidemiology 4.19, 10.100–10.108

expert evidence 10.101, 10.104–10.106

foreseeability 10.96

general/generic causation 10.96, 10.99

hazardous materials, occupational exposure
to 4.19

individual causation 10.96, 10.102–10.109

legal/fault/proximate causation 10.96,
10.110–10.119

material contribution 10.113–10.116

medical negligence and failure to
warn 10.120–10.122

negligence 10.05, 10.94–10.95, 10.110–10.122

partial causation 4.25

pharmacology 10.100, 10.103, 10.105

pharmacovigilance 4.06, 4.11, 4.19–4.22,
4.25–4.27, 4.31, 4.87, 4.100, 4.110, 4.112

Product Liability Directive/CPA

1987 10.35, 10.118

proportionality 4.31

smoking and lung cancer 4.12, 4.31,
10.104, 10.109

standard of proof 10.99, 10.102, 10.108,
10.112–10.113

statistics 10.101, 10.105, 10.108

vaccines 10.118

warnings 10.91, 10.120–10.122

CCR5 gene 3.73–3.74

CE markings 7.38–7.39, 10.128, 15.23, 15.26

cell therapies 3.92–3.122

history 3.92–3.97

somatic cell therapy products 3.98–3.99

stem cells 3.92–3.97, 3.107–3.117

tissue engineered products 3.100–3.102

certainty 4.09–4.14

chemotherapy 5.48, 5.86, 5.91, 5.96, 9.124,
9.130, 11.28

children *see* **paediatric medicine**

Chimeric Antigen Receptor T cells

(CAR-T) 5.49–5.52

Chinese Clinical Trial Register portal 4.162

chloroform 1.06

chloroquine 15.28

cholera epidemic of 1954 4.22

cholesterol 4.136, 4.140–4.143

clinical trials 4.142–4.143

heart disease 4.136, 4.140–4.143

malnutrition 4.140

pharmacovigilance 4.136, 4.140–4.143, 4.172

Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) 4.16–4.18

chondrocyte preparations 3.39–3.40

cisapride 4.131

Citizens Council 6.73

civil law, liability in 10.01–10.170 *see also*

**negligence; Product Liability Directive/
Consumer Protection Act (CPA) 1987;
regulators, liability of**

blood and blood products 10.170

breach of statutory duty 10.04, 10.130–10.131

causation 10.94–10.122

common law 10.02, 10.04–10.15

Congenital Disabilities (Civil Liability) Act
1976 10.169

dispensing pharmacists 10.89–10.91

doctors and other prescribers 10.88

group litigation orders (GLOs) 10.03

health authorities/NHS trusts 10.93

importers 10.87

manufacturers 10.84–10.85, 10.88

producers 10.88, 10.93

specific liabilities 10.84–10.93

Vaccine Damages Payments Act 1979 10.168

warnings 10.88

warranties, breach of 10.04

civil proceedings *see* **civil law, liability in;
litigation**

clastogenesis testing 5.94

- clinical benefit** 2.48, 2.59
- clinical efficacy** 2.01–2.74, 3.41
 - cannabis 9.104, 9.136
 - clinical benefit 2.48, 2.59
 - clinical interpretation 2.40, 2.54–2.58, 2.61
 - clinical judgment 2.41, 2.58
 - clinical trials 2.01–2.74, 4.89–4.91, 8.20
 - context 2.40, 2.44–2.48
 - Covid-19 8.19–8.20, 15.27
 - definition 2.02, 2.28
 - ideal setting, example of a clinical trial in
 - a 2.60–2.61
 - licensing 4.88–4.94
 - patient practices and preferences 2.57–2.58
 - pharmacovigilance 4.09, 4.50, 4.76, 4.88–4.94, 4.167, 4.172
 - process, claims of efficacy as achieved by
 - a 2.40–2.58
 - product development programmes
 - 2.18–2.26
 - psychiatry 4.38, 4.41
 - public health 4.50, 4.167
 - real-world data to make claims for efficacy,
 - use of 2.62–2.69, 2.143
 - risk-benefit analysis 2.03, 2.108, 2.115, 2.119, 4.76, 4.89
 - safety 2.78, 2.79, 2.107
 - statistical analysis 2.40, 2.48–2.53
- clinical hazards** 5.98–5.102
 - clinical implications 5.101–5.102
 - equilibrium, concept of 5.98–5.100
 - small molecules, why biological products
 - differ from 5.98–5.102
- clinical judgment** 2.41, 2.58, 2.90
- Clinical Practice Research Datalink (CPRD)** 2.140–2.143, 4.111, 7.50
- clinical safety** 2.75–2.107
 - adverse events 2.86–2.96, 2.104
 - Brexit 15.16
 - cannabis 9.104, 9.136
 - clinical trials 2.79–2.84, 2.87–2.106, 15.16, 8.22
 - collection of safety data 2.83–2.85
 - Committee for Advanced Therapies (EMA) 3.41
 - continuous process, collecting safety data as
 - a 2.107
 - Covid-19 15.27
 - definition 2.76
 - efficacy 2.03, 2.78, 2.79, 2.107
 - Independent Medicines and Medical Devices
 - Safety Review 15.21
 - initial analysis of safety data 2.86–2.96
 - Medical Dictionary for Regulatory Activities (MedDRA) 2.97–2.102, 2.104
 - Periodic Safety Update Reports (PSURs) 4.113, 4.121, 4.127
 - presentation of safety data 2.103–2.106
 - probability framework 2.78, 2.79
 - recording safety data 2.97–2.102
 - risk-benefit balance 2.108, 2.119
 - stem cells 3.115–3.116
 - treatment emergent adverse events 2.86
 - under-reporting of adverse events 2.85
 - variables 2.80
- clinical superiority** 14.90, 14.93–14.96
- clinical trials** *see also* Clinical Trials Regulation (CTR); clinical trials, regulation of; randomised clinical trials
 - adverse events 2.87–2.102, 4.85, 4.163
 - aims and objectives 2.34–2.35, 2.38, 2.53, 4.84
 - believed, whether data can be 2.55–2.57
 - bias 2.55, 2.70
 - biosimilar medicinal products 3.19, 3.27
 - blood sugar 4.146, 4.148–4.150
 - Brexit 15.15–15.18
 - cannabis 9.133
 - children 8.22, 8.34–8.35, 8.41
 - cholesterol 4.142–4.143
 - clinical interpretation 2.40, 2.54–2.58, 2.61, 2.70–2.74
 - Clinical Trials Directive 1.30, 2.16, 8.01–8.02, 8.21–8.22, 8.39
 - Clinical Trials Information System 2.17, 8.04
 - confirmatory trials 2.21, 2.24
 - consent 6.36, 8.13–8.14, 8.40, 8.42
 - context 2.61, 2.70
 - controlled trials 4.84–4.88, 4.92–4.94, 4.165
 - Covid-19 1.83, 1.85–1.87, 1.101, 15.28–15.30
 - criminal law, liability in 9.17
 - CRISPR 3.73–3.74
 - definition 2.27
 - design 2.27, 2.29–2.39, 2.62, 2.116
 - Dunlop Committee 1.14–1.15
 - efficacy 2.01–2.74, 4.89–4.94
 - endpoints 2.35–2.36, 2.49, 3.19
 - estimands 2.36, 2.38
 - primary 2.35
 - secondary 2.35
 - epidemiology 4.50
 - ethics committees, regulation of 8.22
 - exclusivity rights 12.37
 - exploratory trials 2.21, 2.23, 2.26
 - free of charge, providing trial medicines 8.22
 - funding 4.163
 - gene therapies 3.77–3.78, 3.80
 - Good Clinical Practice (GCP) 2.39, 2.73, 8.22
 - Good Manufacturing Practice (GMP)
 - standards 8.22

clinical trials (*cont.*)

governance domain 2.65
 historical background 2.05, 2.06–2.17
 hypertension 4.138
 ideal setting, example of a clinical trial in
 a 2.60–2.61, 2.70–2.74
 inspections 8.22
 intellectual property and exclusivity
 rights 12.37
 licensing 4.81, 4.84, 4.95–4.96, 4.163
 marketing authorisations 14.10, 14.15,
 14.20, 14.42
 Medicinal Products Directive 11.57
 Medicines and Healthcare products
 Regulatory Agency (MHRA) 2.31, 15.16
 null hypothesis 2.11, 2.49–2.50
 number of patients 2.37
 outcomes 2.61, 2.70
 patient, role of 1.49
 pharmaco-epidemiology 1.31
 pharmacovigilance 4.16, 4.21, 4.50, 4.75,
 4.104, 4.110, 4.163
 controlled trials 4.84–4.88,
 4.92–4.94, 4.165
 efficacy 4.89–4.91
 licensing 4.84, 4.95
 registration 4.159
 risk-benefit balance 4.75, 4.89, 4.92
 signal dilution 4.84–4.88, 4.96–4.97
 spontaneous reporting 4.112
 pharmogenetics 1.65
 phase I (human pharmacology)
 trials 2.22, 2.26
 phase II (therapeutic exploratory) trials 2.21,
 2.23, 2.26
 phase III (therapeutic confirmatory)
 trials 2.21, 2.24
 placebos 1.59, 2.07, 2.15, 4.84, 8.17–8.18
 population and medical condition 2.70
 presentation of safety data 2.103–2.106
 product development programmes 2.18–2.26
 protocol, construct of a 2.32–2.39
 real-world data to make claims for efficacy,
 use of 2.62–2.69
 real world setting, example of a trial in
 a 2.70–2.74
 recruitment 2.141
 registration 4.159, 4.162
 research questions 2.29
 risk-benefit balance 2.64, 2.112, 2.116, 4.75,
 4.89, 4.92
 safety 2.79–2.84, 2.87–2.106, 15.16
 scientific method 2.33
 signal dilution 4.84–4.88, 4.96–4.97

sponsors 15.15, 15.17
 statistics 2.06, 2.08–2.09, 2.12, 2.33, 2.37–
 2.38, 2.49–2.53, 2.61, 2.70
 stem cells 3.110, 5.07
 successful trials 2.53
 technical and operational
 issues 2.65–2.66, 2.71
 therapeutic confirmatory trials 2.23
 trade marks 13.98
 transparency 4.153–4.158
 vaccinations 2.06
 variables 2.55–2.56
 withdrawals 4.128

Clinical Trials Regulation (CTR) 2.17, 8.03–

8.10, 8.39–8.54
 application dossiers 8.45–8.52
 scientific documents (Part I) 8.46–8.52
 specific information (Part II) 8.46–8.52
 authorisation process 8.45–8.52
 Brexit 8.04–8.10, 8.58
 capacity 8.41
 Clinical Trials Directive 8.39
 Clinical Trials Information System (CTIS) 8.44
 Concerned Member States (CMS) 8.45,
 8.48–8.49
 derogations 8.42
 ethics committees 8.45–8.46, 8.50, 8.56
 harmonisation 8.44
 informed consent 8.40, 8.42
 inspections 8.53–8.54
 low-intervention clinical trials 8.43
 multinational trials 8.58
 National Competent Authorities 8.45
 notifications 8.55
 Paediatric Regulation 8.34–8.35
 reporting Member State
 (RMS) 8.47–8.48, 8.51
 sponsors 8.44, 8.47, 8.51, 8.55
 supplementary Commission Delegated
 Regulation 8.54
 traceability 8.43
 transparency 8.38, 8.57

clinical trials, regulation of 1.58–1.61, 8.01–8.58

amendments 8.28
 approval 8.03, 8.29
 assessment of applications by competent
 authorities 8.29
 Brexit 8.04–8.10, 8.35
 Clinical Trials Directive 8.01–8.02
 Clinical Trials Expert Advisory Groups
 (EAGs) 8.29
 Clinical Trials Information System
 (CTIS) 8.04, 8.07–8.09, 8.58
 comparators 1.59

- consent 8.13–8.14
- costs and funding 1.60, 8.02
- Covid-19 8.19–8.20
- delay 8.02
- efficacy 8.20
- ethics of clinical trials 8.11–8.20
- European Clinical Trials register 8.30
- experts 8.29, 8.36
- first-in human studies 8.32
- Good Clinical Practice (GCP)
 - Directive 8.21, 8.23
- Good Manufacturing Practice (GMP)
 - Directive 8.24–8.25, 8.28
- healthy volunteers or patients 1.59
- Helsinki Declaration 8.12, 8.15, 8.18
- Medicines and Healthcare products
 - Regulatory Agency (MHRA) 8.21, 8.27, 8.29
- multinational trials 8.02–8.03
- non-acceptance, grounds for 8.29
- number of patients 1.58
- number of trials, decrease in 8.02
- paediatric trials 8.33–8.35
- placebos 1.59, 8.17–8.18
- publication of clinical trials 8.36–8.38
- randomised controlled trials 8.17
- registries, role of patient 1.60
- risk-benefit balance 1.60, 8.15–8.16
- specified actions, taking 8.29
- sponsors 8.28
- timelines 8.27
- transparency 8.37–8.38
- clofibrate 4.140–4.141
- clozapine 4.132
- Commission on Human Medicines
 - (CMA) 8.29, 10.07, 10.125, 10.130
- Committee for Advanced Therapies
 - (EMA) 3.41–3.45
- Committee for Medicinal Products for Human Use (CHMP) 1.19, 3.43, 3.44, 4.120, 13.96
- Committee on the Safety of Drugs (CSD)
 - (Dunlop Committee) 1.14–1.18, 1.22
- Committee on the Safety of Medicines
 - (CSM) 1.17–1.18, 1.28–1.29
- common law 10.02, 10.04–10.15, 12.01–12.02, 12.30, 13.110
- companies and
 - pharmacovigilance 4.113–4.129
- competition law 9.32, 9.34, 13.111, 13.121
- concealment 9.16
- confidential information 12.13, 12.30–12.32
 - common law 12.30
 - criminal law, liability in 9.78
 - detriment 12.31
 - employee-employer relationship 12.31
 - intellectual property and exclusivity
 - rights 12.07, 12.13, 12.30–12.32
 - medical devices 7.76
 - Medicines and Healthcare products
 - Regulatory Agency (MHRA) 7.76
 - patents 12.32, 13.21
 - perpetual monopoly, as 12.32
 - public domain 12.07
 - quality of confidence 12.31
 - reverse engineering 12.32
 - three-limb test 12.30
- confiscation orders 9.91, 9.98–9.100, 9.112, 9.116, 9.119
- conformity assessments 7.03, 7.33–7.37, 7.39, 7.58, 7.63, 7.71
- Congenital Disabilities (Civil Liability) Act 1976** 10.169
- consensus statements 7.67
- consent**
 - capacity 8.13
 - causation 10.121–10.122
 - clinical trials 6.36, 8.13–8.14, 8.40, 8.42
 - criminal law, liability in 9.15
 - informed consent 8.40, 8.42, 10.121–10.122, 11.42
 - law enforcement agencies and their
 - methods 9.76
 - medical negligence 10.121–10.122
 - orphan market exclusivity 14.90–14.91
- conspiracy 9.17, 9.34
- Consumer Protection Act (CPA) 1987** *see* **Product Liability Directive/Consumer Protection Act (CPA) 1987**
- continuous positive airway pressure (CPAP)
 - machines 1.90, 15.33
- contribution 10.14, 10.81–10.82, 10.91, 11.24
- contributory negligence 10.11, 10.70
- controlled drugs regime 9.03, 9.19–9.27
 - articles for use in administration of controlled
 - drugs 9.23
 - classification of drugs 9.20–9.22
 - directions, making and enforcement
 - of 9.24–9.25
 - exceptions 9.27
 - intellectual property offences 9.33
 - licensing 9.03
 - overseas, assisting in or inducing a drug
 - offence 9.26
 - prescription-only medicines, diversion
 - of 9.22
 - principal offences 9.19–9.22
 - prosecutions, examples of 9.21–9.22
 - sentencing 9.20, 9.25–9.27

- copyright** 12.01, 12.13, 12.22–12.26
 - artistic, literary, dramatic or musical works 12.23
 - Berne Convention 1886 12.11
 - exclusivity 12.01, 12.13, 12.22–12.26
 - independent creation of works 12.26
 - purpose 12.22
 - term of protection 12.06, 12.25
- coronavirus** *see* Covid-19 pandemic
- corporate criminal liability** 9.28–9.31, 9.42–9.43
 - corporate manslaughter 9.42–9.43
 - gross negligence 9.12–9.13, 9.42
 - senior management 9.42
 - directing mind and will 9.28, 9.30
 - directors 9.28–9.31, 9.42
 - failure to prevent offences 9.44
 - health and safety offences 9.43
 - mens rea* 9.30
 - officers of an offending corporate entities, liability for 9.31
 - regulatory offences 9.30
 - strict liability 9.30
- costs and funding** 11.26–11.31
 - advanced therapy medicinal products (ATMPs) 3.103
 - biosimilar medicinal products 3.27
 - brands 6.21–6.22
 - Cancer Drugs Fund 6.43–6.44
 - clinical trials 1.60, 4.163, 8.02
 - decisions on funding 11.26–11.31
 - exceptional circumstances 11.31
 - gender reassignment treatment 11.29–11.30
 - gene therapies 3.88
 - group litigation orders (GLOs) 10.03
 - irrationality 11.31
 - legal costs 10.03, 11.16
 - life, right to 11.35–11.36
 - NICE 6.06, 6.09, 6.15–6.16, 6.25–6.32, 6.66, 11.31, 11.46–11.47
 - patents 13.03
 - resources 11.27–11.31
 - social care 6.15
- counselling services** 15.45
- counterfeiting** 9.33, 9.41, 9.81
- Covid-19 pandemic** 1.80–1.94, 1.100, 15.27–15.34
 - accelerated assessments 15.27
 - antibody testing 1.89, 1.93, 15.32
 - antigen testing 1.92
 - big data 5.104
 - clinical trials 1.83, 1.85–1.87, 1.101, 8.19–8.20, 15.28–15.30
 - continuous positive airway pressure (CPAP) machines 1.90, 15.33
 - diagnostic medical devices 1.87, 1.89, 1.92, 1.94
 - efficacy 8.20, 15.27
 - European Medicines Agency (EMA) 1.83–1.86, 15.27–15.29
 - Interferon-alfa 5.38
 - marketing authorisation, acceleration of 1.83–1.84, 15.27
 - masks, use of 1.95–1.97
 - medical devices 1.87, 1.89, 1.94, 1.99, 7.03, 7.73, 7.84
 - medical records, remote access to 15.30
 - Medicines and Healthcare products Regulatory Agency (MHRA) 1.83, 1.87–1.90, 1.94, 8.20, 15.30–15.33
 - Medicines Directive, guidelines on implementation of 1.84, 15.27
 - monoclonal antibodies 15.28
 - mRNA (messenger mRNA) 5.84
 - NICE, review of guidelines by 1.101
 - oxygen therapy 1.97
 - personal protective equipment (PPE) 1.90, 1.95–1.97
 - PRIME scheme 1.84, 15.27
 - procurement 1.82
 - Public Readiness and Emergency Preparedness Act (PREP) 1.83
 - rapid test kits 1.92, 1.94
 - regulation 1.80–1.88, 15.31–15.32
 - safety 15.27
 - testing kits 1.92–1.94
 - vaccines 1.84, 1.86, 1.101, 5.84, 5.104, 8.20, 15.29
 - variations 1.88
 - ventilators 1.90, 1.97, 1.100, 15.33
 - WHO 1.85, 1.101, 8.20, 15.28
- COX 2 inhibitors** 4.143
- criminal law, liability in** 9.01–9.160 *see also*
 - controlled drugs regime; defences to criminal liability; fraud; proceeds of crime
- advertising 9.67–9.72
- aiding, abetting, counselling and procuring 9.17
- assisting or encouraging 9.17–9.18
- attempts 9.17
- Brexit 9.50
- bribery 9.44–9.45
- cannabis-based products for medicinal use (CBPMs) 9.03
- causation 9.14–9.16
- competition law 9.32, 9.34

- concealment 9.16
- confidential material 9.78
- consent 9.15
- conspiracy 9.17, 9.34
- corporate criminal liability 9.28–9.31, 9.42–9.43
- corporate manslaughter 9.42–9.43
- counterfeiting 9.33, 9.41, 9.81
- data protection offences 9.46
- deception 9.16
- Deferred Prosecution Agreements (DPAs) 9.92
- disclosure 9.77
- distance, sale of medicines to the public at a 9.66
- duress of circumstances 9.15
- enforcement 9.73, 9.74–9.102
- EU law 9.47, 9.50, 9.85
- false good laboratory practice instruments 9.48
- foreseeability 9.08, 9.12–9.13
- grievous bodily harm (GBH) 9.05–9.06, 9.08
- gross negligence manslaughter 9.12–9.13
- homeopathic, traditional herbal, and borderline products 9.64
- Human Medicines Regulations 2012 9.36, 9.49, 9.56–9.73
- inchoate offences 9.17–9.18
- intellectual property offences 9.32–9.33
- internal investigations 9.82
- interviews 9.83
- investigations 9.74–9.91
 - confidential material, production and seizure of medical 9.78
 - internal investigations 9.82
 - international aspects 9.85
 - law enforcement agencies and their methods 9.74–9.77, 9.86, 9.92
 - production orders 9.77
 - strategic considerations 9.80–9.81
- law enforcement agencies and their methods 9.02, 9.74–9.77, 9.86, 9.92
- leaflets 9.67–9.72
- licensing 9.61–9.63
- manslaughter 9.05–9.06, 9.09–9.12
- marketing authorisations 9.61–9.63
- medical devices, offences under safety regulations with regard to 9.55
- Medicines Act 1968 9.51–9.54
- Medicines and Healthcare products Regulatory Agency (MHRA) 9.02, 9.72, 9.79–9.80, 9.85–9.92
- mens rea* 9.07–9.09, 9.14, 9.17
- money laundering 9.35–9.40, 9.88
- murder 9.05–9.06, 9.08–9.09
- Mutual Legal Assistance (MLA) 9.85
- necessity 9.15
- non-prosecution disposals 9.92
- offence-creating provision, basis for 9.47–9.50
- offences against the person 9.05–9.16
- overseas, conduct 9.88–9.90
- packaging 9.67–9.72
- pharmacovigilance 9.65
- poison, maliciously administering 9.08
- price-fixing prosecutions against pharmaceutical companies 9.34
- primary legislation 9.47–9.49
- product safety investigations 9.79
- production orders 9.77
- professional disciplinary and debarment procedures, interaction with 9.102
- prosecution and outcome 9.93–9.101
- regulation 9.03, 9.47–9.73
- relevance of criminal law 9.05–9.18
- searches 9.77
- secondary legislation 9.47–9.49
- seizure 9.77, 9.78
- specific intent 9.08
- strategic considerations 9.80–9.81
- Trading Standards 9.74, 9.79
- warranties, intentional or reckless provision of false 9.69
- CRISPR** 3.65, 3.67–3.75, 3.82
 - antibiotics 3.75
 - CCR 5 gene 3.73–3.74
 - CRISPR-Cas, components of 3.70
 - CRISPR-Cas 9 3.67, 3.68, 3.70–3.72
 - CRISPR-Cas 13 3.67
 - DNA 3.67, 3.68, 3.70, 3.74–3.75
 - endonucleases 3.68
 - locus 3.69
 - RNA 3.67, 3.68, 3.70, 3.72
- Cumberlege Review *see* Independent Medicines and Medical Devices Safety Review 2020**
- cytokines** 5.37–5.39, 8.32
- cytosine** 5.58, 5.60
- damages**
 - causes of action 11.15
 - contribution 10.14
 - contributory negligence 10.11
 - Human Rights Act 1998 11.15, 11.23
 - judicial review 11.15
 - Product Liability Directive/CPA 1987 10.73
 - Vaccine Damages Payments Act 1979 10.168
- data exclusivity** 12.36–12.39, 14.02–14.24
 - ‘+ 1’ market exclusivity right 14.18–14.19

data exclusivity (*cont.*)

- abridged marketing authorisations 14.13–14.17, 14.20–14.24, 14.40
- additional year of exclusivity 14.42–14.45
- bridging data 14.25–14.28
- derogations 14.90–14.97
- generics 14.04–14.08, 14.21–14.24
- Generics 14.04–14.08
- global marketing authorisations (GMAs) 14.25–14.108
- market exclusivity 14.03, 14.10, 14.12–14.17, 14.21, 14.107–14.108
- marketing authorisations 12.36–12.39, 14.04–14.108
- Medicinal Products Directive 12.36–12.39, 14.04–14.10
- new active substance (NAS) concept 14.24, 14.35–14.41
- orphan market exclusivity 14.46–14.14.108
- paediatric exclusivity 14.98–14.108
- reference medicinal product 14.04–14.09, 14.14–14.15, 14.25
- similar medicinal products 14.78–14.89
- trigger date 14.12

data protection offences 9.46**databases** 4.105–4.108, 4.168, 8.33

- case reports 4.101–4.102, 4.105–4.108, 4.111
- Clinical Practice Research Datalink (CPRD) 2.140–2.143, 4.111, 7.50
- EudraCT database 8.30, 8.36, 8.57
- EudraVigilance database 4.102, 4.106, 4.118, 4.161, 8.31, 8.56
- FDA's MedWatch 4.102, 4.108
- patents 13.54
- personalised medicine 4.160
- spontaneous reports 4.106–4.108
- transparency 8.57
- WHO's Uppsala database 4.102, 4.105, 4.162

deception 9.16, 13.110**declarations** 11.23**defective goods** *see* **Product Liability Directive/Consumer Protection Act (CPA) 1987****defences to criminal liability**

- cannabis 9.119
- criminal law, liability in 9.14–9.16
- development risks defence 10.18, 10.64–10.68
- mandatory regulations defence 10.62–10.63
- money laundering 9.39
- Product Liability Directive/CPA 1987 10.57–10.70
- subsequent defects defence 10.60
- uncirculated products defence 10.58–10.59

Deferred Prosecution Agreements

(DPAs) 9.92

defibrillators and pacemakers 10.27**deoxyribonucleic acid** *see* **DNA** (deoxyribonucleic acid)**design rights** 12.08, 12.13, 12.27–12.29

- exclusivity 12.08, 12.13, 12.27–12.29
- offences 13.116, 13.120
- registered rights 12.27, 13.120
- term of protection 12.06
- unregistered rights 12.27, 13.120

destitution 11.39**Dexdor** 11.57**dexfenfluramine** 4.86**diabetes**

- blood sugar 4.144–4.152
- heart attacks 4.25, 4.112, 4.166
- insulin 5.07, 5.12, 5.17, 5.20–5.21, 5.23
- rosiglitazone 4.89, 4.112, 4.144–4.152, 4.166
- UK Prospective Diabetes Study (UKPDS) 4.145

directors, liability of 9.28–9.31, 9.42, 10.15**disabilities** 3.88, 10.12**disciplinary and debarment procedures, interaction with professional** 9.102**dispensing pharmacists** 10.89–10.91**distance, sale of medicines to the public at a** 9.66**DNA (deoxyribonucleic acid)** 5.04, 5.07, 5.53–5.77 *see also* **human genome**

- adenine 5.58, 5.60
- amino acids 5.60, 5.65–5.67
- bacteria 5.93
- base pairs 5.58–5.60, 5.65
- big data 5.105
- biological products 5.04, 5.07, 5.53–5.77
- Central Dogma of Molecular Biology 5.59
- codons 5.60, 5.66
- CRISPR 3.67, 3.68, 3.70, 3.74–3.75
- cytosine 5.58, 5.60
- double helix 5.53–5.62
- enzymes 5.66, 5.68
- errors 5.61–5.62
- genes 5.65–5.68
 - editing 3.62–3.63, 3.66–3.67
 - genetic code, definition of 5.60
 - genetic engineering 5.04, 5.70
 - therapies 3.83–3.87, 5.70–5.77
- genotoxicity and carcinogenicity, testing for 5.88, 5.93
- junk DNA 5.67
- manufacture 5.63–5.64, 5.70–5.77
- messenger RNA (mRNA) 5.59, 5.71
- mutations 5.62, 5.66, 5.93
- polymerase chain reaction (PCR) 5.64, 5.71
- proteins 5.61, 5.65, 5.68
- repair mechanisms 5.62

- RNA 5.59, 5.70–5.71, 5.78–5.84
- staircases 5.54–5.56
- stop codes 5.60
- TAG, TAA and TGA 5.60
- thymine 5.58, 5.60
- doctors, liability of** 10.88
- dronabinol** 9.130
- drug device combinations** 1.67, 1.68–1.70
- drug offences** *see* **controlled drugs regime;**
 medicinal cannabis
- Dunlop Committee (Committee on Safety of**
 Drugs (CSD)) 1.14–1.18, 1.22
- duress of circumstances** 9.15
- ectopic tissue formation** 3.108
- efficacy** *see* **clinical efficacy**
- electronic health records** 2.65, 2.71, 2.74, 2.141
- EMA** *see* **European Medicines Agency (EMA)**
- embryos** 3.92–3.96, 3.111–3.117, 3.120
- endonucleases** 3.68
- enforcement**
 - cannabis 9.117
 - criminal law, liability in 9.73, 9.74–9.102
 - law enforcement agencies and their
 methods 9.02, 9.74–9.77
 - medical devices 7.13, 7.15, 7.49, 7.65,
 7.74–7.83
 - parallel trade 13.100
 - quality 1.08–1.10, 1.15
 - trade marks 13.108–13.109, 13.119
- enzymes** 5.17–5.18, 5.20, 5.22, 5.66, 5.68
- epidemiology**
 - blood sugar 4.145
 - causation 4.19, 10.100–10.108
 - pharmaco-epidemiology 1.31
 - pharmacovigilance 4.22, 4.32, 4.50, 4.97, 4.172
- Epidiolex** 9.146
- epilepsy** 15.36, 15.47
- equality legislation** 6.17, 6.69
- ethical issues**
 - big data 5.105
 - clinical trials 8.11–8.20, 8.28, 8.45–8.46,
 8.50, 8.56
 - consent 8.13–8.14
 - Covid-19 8.19–8.20
 - enhance human traits, use of gene therapy
 to 3.88
 - ethics committees 8.16, 8.28, 8.45–8.46,
 8.50, 8.56
 - gene therapies 3.88–3.91
 - Health Research Authority (HRA) 3.129
 - patents 13.51
 - pharmogenetics 1.66
 - placebos 8.17–8.18
 - risk-benefit balance 8.15–8.16
 - stem cells 3.113, 5.46
 - trade marks 13.89
- EudraCT database** 8.30, 8.36, 8.57
- Eudrallex** 3.49
- EudraVigilance database** 4.102, 4.106, 4.118,
 4.161, 8.31, 8.56
- European Convention on Human Rights**
 (ECHR) 11.32–11.43
 - Human Rights Act 1998 11.17–11.18,
 11.23, 11.25
 - inhuman or degrading
 treatment 11.38–11.41
 - life, right to 11.33–11.37
 - private and family life, right to respect
 for 11.42–11.43
- European Directorate for Quality of**
 Medicines 15.04
- European Medicines Agency (EMA)** 1.39–1.46
 - big data 2.137–2.139
 - biosimilar medicinal products, guidelines
 on 3.20
 - Brexit 8.04
 - clinical trials 2.17, 2.31, 8.04
 - Committee for Advanced Therapies 3.41–3.45
 - Covid-19 1.83–1.86, 15.27–15.29
 - efficacy 2.44–2.48
 - European Medicines Directive (2004/27),
 development of 1.42–1.43
 - European Network of Centres for
 Pharmacoepidemiology and
 Pharmacovigilance (ENCePP)
 (EMA) 4.106
 - harmonisation 1.40–1.41, 8.44
 - marketing authorisation 1.39–1.40, 1.44,
 14.49, 14.59, 14.82–14.88
 - medical devices 3.45, 7.49, 7.52, 7.71
 - medicinal product, definition of 1.44
 - orphan market exclusivity 14.49, 14.59,
 14.82–14.88, 14.95
 - paediatric exclusivity 14.98
 - parallel trade 13.105–13.106
 - pharmacovigilance 1.40, 4.26, 4.107, 11.59
 - recommendations 2.139
 - regulation 1.45–1.46, 4.118–4.119, 10.124
 - relocation 8.04
 - risk-benefit balance 1.20, 2.117–2.119
 - stem cell tourism 3.109
 - vaccines 15.29
 - WHO 15.28
- European Network of Centres for**
 Pharmacoepidemiology and
 Pharmacovigilance (ENCePP)
 (EMA) 4.106

- European Patent Convention (EPC)** 13.10, 13.12, 13.17, 13.28–13.29, 13.66–13.69
- European Patent Office (EPO)** 13.12–13.13, 13.15, 13.17–13.18, 13.28, 13.55
- European Pharmacopoeia** 15.11
- European Union** *see also* **Brexit**; **Clinical Trials Regulation (CTR)**; **European Medicines Agency (EMA)**; **medical devices (European Union)**; **Product Liability Directive/Consumer Protection Act (CPA) 1987**
- Active Implantable Medical Devices Directive 6.51–6.52, 7.09, 7.19
- adverse effects 1.32
- ATMP Regulation 3.34–3.40
- biosimilar medicinal products 3.17
- Biotech Directive 13.48–13.49
- Blood Directive 3.126–3.127
- clinical trials 1.21, 1.30, 2.16–2.17, 8.01–8.02, 8.35
- collaboration 4.161–4.162
- criminal law, liability in 9.47, 9.50
- efficacy 2.02
- European Clinical Trials register 8.30
- gene therapies 3.80–3.81
- Innovative Medicines Initiative (IMI) 1.57
- marketing authorisations 1.32, 1.37
- Medicinal Products Directive 11.52–11.59
- Medicines Act 1968 9.47
- Medicines Directive 1.42–1.43, 1.84, 15.27
- Mutual Legal Assistance (MLA) 9.85
- orphan market exclusivity 14.68–14.77
- parallel trade 13.99–13.107
- passing off 13.111
- patents 13.12–13.14
- personal protective equipment (PPE) 1.96–1.97
- pharmacovigilance 1.32, 4.161–4.162
- regulation 1.36–1.38, 12.33–12.39
- risk-benefit concept 1.19, 1.38
- supplementary protection certificates (SPCs) 13.70, 13.72–13.73
- Tissue and Cells Directive 3.58, 3.124, 3.133–3.135
- trade marks 13.12, 13.84, 13.100, 13.108–13.109
- exclusivity** *see* **data exclusivity**; **exclusivity rights and intellectual property**
- exclusivity rights and intellectual property** 12.01–12.51
- clinical trials 12.37
- common law 12.01–12.02
- confidential information 12.07, 12.13, 12.30–12.32
- copyright 12.01, 12.13, 12.22–12.26
- court proceedings 12.09
- design rights 12.08, 12.13, 12.27–12.29
- industrial property 12.01
- intellectual property rights, definition of 12.01–12.03
- international in character, IPRs as 12.11
- limited duration, IPRs as being of 12.06
- marketing authorisations
- abridged 12.36, 12.38
- full 12.36–12.38
- regulatory exclusivities 12.33–12.39
- medicines, application to 12.12–12.13
- national in character, IPRs as 12.11
- negative/exclusory rights, IPRs as 12.05
- patents 12.08, 12.10–12.11, 12.13–12.16
- proprietary, IPRs as 12.04
- registration 12.08
- regulatory exclusivities 12.33–12.52
- research and development, costs of 12.12, 12.33
- restricted scope of IPRs 12.08–12.10
- statutory regimes 12.01–12.02
- term of protection 12.06–12.07
- trade marks 12.08, 12.13, 12.17–12.21
- experts**
- causation 10.101, 10.104–10.106
- clinical trials 8.29, 8.36
- Devices Expert Advisory Committee (DEAC) 10.130
- Infected Blood Inquiry 15.57–15.59
- medical devices 7.50–7.52
- Medicines and Healthcare products Regulatory Agency (MHRA) 15.48
- mesothelioma and *Fairchild* exception 10.106
- NICE 6.38, 6.42, 6.47, 6.72
- pharmacovigilance 4.161
- fatal accidents** 10.13, 10.76
- fault**
- causation 10.96, 10.110–10.119
- negligence 10.02, 10.08, 10.11–10.12, 10.94
- Product Liability Directive/CPA 1987 10.30, 10.35, 10.70
- FDA** *see* **Food and Drug Administration (FDA) (United States)**
- fenfluramine** 4.86
- feprazone** 4.131
- fermentation** 5.05
- fertility treatment** *see* **Human Fertilisation and Embryology Authority (HFEA)**
- flecainide** 4.132
- fomivirsen** 5.86